Patients in hospital Intensive Care Units (ICU) may experience impairment in their ability to breathe volitionally due to their underlying disease condition and require positive pressure mechanical ventilation (PPMV) to provide ventilatory assistance. PPMV is routinely used in combination with sedation in the ICU to provide artificial ventilation for these critically ill individuals. Additionally, many patients undergoing surgery under general anesthesia, for example in hospital Operating Rooms (OR), or procedures under anesthesia or sedation, for example in hospital Emergency Rooms (ER), commonly require PPMV for ventilatory assistance while anesthetized or sedated.
Although mechanical ventilation is a life-sustaining modality, when combined with sedation or anesthesia it interferes with active contraction of the diaphragm. Prolonged totally controlled mechanical ventilation can result in the complete absence of neural activation and mechanical activity of the diaphragm and has been shown to induce muscle atrophy, proteolysis, and reactive oxygen species liberation, leading to rapid loses in diaphragmatic function, a syndrome known as Ventilator-Induced Diaphragmatic Dysfunction (VIDD).
The onset of diaphragm disuse atrophy is rapid, leading to slower patient recovery, which often results in ventilator dependence and translates into higher incidence of ventilator-acquired pneumonia and nosocomial infections, longer stays in the ICU, and escalating hospitalization costs.
In addition to ICU patients, mechanical ventilation is the primary modality of ventilatory assistance for individuals with disease conditions that adversely affect neurological function, such as Spinal Cord Injury (SCI). These individuals may experience impairment in their ability to breathe volitionally due to partial or complete loss of control of the diaphragm, and are prone to lifelong dependence on a mechanical ventilator.
Several viable alternatives to PPMV for assisting breathing are currently available, and have been indicated for use in patients requiring long-term ventilatory assistance such as Spinal Cord Injury (SCI) patients or patients with Congenital Central Hypoventilation Syndrome (CCHS). They include phrenic nerve stimulation and diaphragmatic pacing. These methods use electrical stimulation to induce contraction of the diaphragm using an electrode and an external pacing control box or an implanted pacemaker device.
The two phrenic nerves, which control activation of the diaphragm, run through the thorax, along the left and right sides of the heart, and then to the diaphragm. Phrenic nerve stimulation is performed by electrically stimulating the phrenic nerve to control the patient's diaphragm, which may induce a respiratory cycle. Conventional techniques include surgically implanting a nerve cuff around the phrenic nerve (at the neck or chest level), and then delivering an electrical stimulus from an externally located controller through the cuff to the phrenic nerve. This procedure is quite invasive, requiring incisions when deploying the nerve cuffs, and quite expensive, so it is only selectively used in patients with a life-long requirement for assisted ventilation. In addition, the direct placement of the nerve cuffs around the phrenic nerves may damage the phrenic nerves. These phrenic nerve stimulation systems have not heretofore been prescribed for temporary use in critically ill ICU patients.
Other phrenic nerve stimulation techniques are known, such as that described in U.S. Pat. No. 8,195,297. However, the system disclosed in the '297 patent does not allow for rapid, short term use in an ICU environment for the management of ICU patients particularly in the first few days after start of PPMV.
Another method for electrically stimulating the diaphragm is known as diaphragmatic pacing. Conventionally, diaphragmatic pacing is performed by laparoscopically implanting four electrodes directly on the diaphragm (two on each side), with electrical leads connected to a controller residing external to the body. Conventional diaphragmatic pacing procedures are also quite time consuming and relatively invasive, requiring incisions during implantation, presenting risk during the implantation procedure and risk of chronic infection at the lead entrance sites to the body. Accordingly, these diaphragmatic pacing systems have not heretofore been prescribed for temporary use in critically ill ICU patients.
One such diaphragmatic pacing system is described in U.S. Pat. No. 7,962,215. In addition to being surgically demanding, the diaphragmatic pacing system of the '215 patent is employed to administer therapy to convert Type IIa (fast-type) muscle fibers to Type I (slow-type) muscle fibers in patients who have been ventilated for prolonged periods, whose muscle fibers have all atrophied and converted to Fast-type (VIDD). The therapy described in the '215 patent, however, will not be desirable in the treatment of critical care patients that still have both Type IIa (fast-type) muscle fibers and Type I (slow-type) and will need to have both types to successfully wean off of PPMV.
Accordingly, there exists a need for minimally invasive diaphragm pacing systems and methods for rapid, short term use, as appropriate in the ICU environment, for the management of ICU patients particularly in the first few days or weeks after start of PPMV.
Examples of systems and methods disclosed herein address this need and others by providing a minimally invasive nerve stimulation system that paces the phrenic nerves transvascularly via disposable endovascular electrodes that can be percutaneously placed under local anesthesia. As will be described in the Detailed Description, such pacing systems and methods can be employed to provide short periods of electrical stimulation for preventing diaphragm disuse atrophy in patients at risk of becoming ventilator-dependent and/or to rehabilitate diaphragm disuse atrophy in ventilator-dependent patients.
The system is designed to work either in conjunction with a mechanical ventilator, causing diaphragmatic contractions in synchrony with each ventilator administered breath, intermittently synchronized to some ventilator breaths, or as a stand-alone system. In some embodiments, the systems and methods may be employed just minutes or hours after first intubation of the subject. Such diaphragm pacing therapy is expected to prevent, reduce or reverse diaphragm disuse atrophy that typically occurs in patients who are on PPMV or are expected to require PPMV and sedation for prolonged periods and by extension, the adverse effects associated with PPMV will be avoided or reduced. As a result, patients may be successfully weaned from PPMV earlier than currently known methods, providing drastic health benefits to patients not to mention substantial reductions in total in-patient costs.
In accordance with one aspect of the present disclosure, a method is provided for administering a treatment plan designed for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The ventilator is employed to provide a breath cycle to the patient, the patient having a prescribed assist level. The method comprises monitoring the breath cycle of the ventilator, administering a pre-programmed stimulation signal to the patient to recruit the phrenic nerve of the patient, and regulating the diaphragm output of the patient for each breath cycle. In some embodiments, the stimulation signal is administered via one or more endovascular electrodes.
In accordance with a first embodiment, the administration of the stimulation signal can occur within a time period, such as 1 hour, 3 hours, 6 hours, 12 hours, 1 day, 3 days, and 1 week, of the patient's first reception of respiratory assistance from the ventilator.
In accordance with a second embodiment, the method also includes obtaining data indicative of at least one of: one or more ventilator breath parameters; one or more pacing parameters; and a prescribed assist level for the patient.
In accordance with a third embodiment, the one or more ventilator breath parameters includes timing data indicative of the duration of a ventilated breath.
In accordance with a fourth embodiment, the method also includes maintaining synchrony between the delivery of the stimulation signal and the ventilator breath cycle.
In accordance with a fifth embodiment, maintaining synchrony includes determining the current breath cycle via data from one or more sensors, and comparing the current breath cycle with the timing data from at least one previous breath cycle.
In accordance with a sixth embodiment, recruitment of the diaphragm provides at least a portion of the prescribed assist level.
In accordance with a seventh embodiment, the method further comprises determining a diaphragm contribution level attributable to the administration of the stimulation signal, wherein the prescribed assist level is the sum of the diaphragm contribution level and a ventilator contribution level.
In accordance with an eight embodiment, the simulation signal includes stimulation signal characteristics that cause the stimulation signal, when delivered to the patient, to satisfy the diaphragm contribution level.
In accordance with a ninth embodiment, the diaphragm contribution level is measured in tidal volume or pressure, individually, in combination, and including components thereof.
In accordance with a tenth embodiment, the prescribed diaphragm contribution level is dependent on the condition of the patient and the contractile capacity and/or functional status of the diaphragm.
In accordance with a eleventh embodiment, determining the contractile capacity includes measuring strength and endurance from the response of the diaphragm to test stimulation patterns.
In accordance with a twelfth embodiment, the condition of the patient and contractile capacity of the diaphragm and/or functional status of the phrenic nerves are assessed prior to the administration of the treatment plan and/or during administration of the treatment plan.
In accordance with a thirteenth embodiment, determining the strength and endurance of the patient's diaphragm includes measuring maximum diaphragm output and fatigue characteristics of the diaphragm.
In accordance with a fourteenth embodiment, monitoring the breath cycle includes sensing breath cycle data via a breath sensor discrete from and interfaced with a breathing circuit of the ventilator and the patient airway, and determining the inspiration phase and the expiration phase of the breath cycle and the duration of each phase from the sensed breath cycle data.
In accordance with a fifteenth embodiment, monitoring the breath cycle further includes determining at least one of the amplitude and rate of change of ventilator output signals for each breath.
In accordance with a sixteenth embodiment, administering a stimulation signal includes generating a stimulation signal in accordance with one or more pacing parameters; and delivering the stimulation signal in relation to a ventilator breath cycle.
In accordance with a seventeenth embodiment, regulating the diaphragm output of the patient for each breath cycle, such as a paced breath cycle, includes monitoring the diaphragm output in response to the last administered stimulation signal; and comparing the diaphragm output of the last administered stimulation signal to a preset target range. Alternatively, the method can skip pacing for one breath cycle (MV-Only), but stimulate the at the next breath cycle (i.e., mechanical ventilation and diaphragm pacing. The method can then compare both of these values and regulate the next paced breath.
In accordance with an eighteenth embodiment, monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, wherein the diaphragm output data is indicative of one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure; and processing the sensed diaphragm data to determine the diaphragm output.
In accordance with a nineteenth embodiment, regulating the diaphragm output of the patient for each breath cycle further includes modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
In accordance with a twentieth embodiment, the preselected target range includes a diaphragm contribution level.
In accordance with a twenty-first embodiment, the method further comprises determining a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
In accordance with a twenty-second embodiment, if the cause is due to a variation in the respiratory mechanics of the patient, then the condition of the patient's diaphragm and respiratory system during administration of the treatment plan is assessed.
In accordance with a twenty-third embodiment, the method further comprises reprogramming the stimulation signal based on the condition of the assessed diaphragm.
In accordance with a twenty-fourth embodiment, assessing the diaphragm includes monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay; progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determining one or more functional characteristics of the diaphragm and respiratory system, wherein the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, Electromyogram (EMG), Maximum Relaxation Rate, and Expiration Time Constant.
In accordance with a twenty-fifth embodiment, the diaphragm stimulation is targeted to take place during each ventilator breath in order to reduce positive pressure and reduce the risk of Ventilator Induced Lung Injury (VILI).
In accordance with a twenty-sixth embodiment, monitoring the breath cycle of the ventilator includes sensing signals indicative of ventilator inspiration and expiration; and calculating one or more of: inspiration phase; expiration phase; inspiration pause; expiration pause.
In accordance with a twenty-seventh embodiment, administering the stimulation signal includes delivery of the stimulation signal contemporaneously with inspiration phase.
In accordance with anther aspect of the present disclosure, a transvascular diaphragm pacing system is provided for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The system comprises at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient, the stimulation signal in some embodiments have one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, and a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to: receive input data indicative of one or more aspects of the therapy plan, wherein the input data includes sensed signals indicative of ventilator operation and one or more pacing parameters; monitor the breath cycle signals and determine the inspiration phase and expiration phase of the breath cycle; generate the stimulation signal according to the one or more pacing parameters and delivering the generated stimulation signal to the at least one transvascular electrode at a preselected time of the ventilator breath cycle; and regulate the diaphragm output of the patient for each breath cycle.
In accordance with a twenty-eighth embodiment, the controller is further programmed to regulate the diaphragm output of the patient to satisfy a prescribed assist level of the patient.
In accordance with a twenty-ninth embodiment, the controller is further programmed to maintain synchrony of the delivery of the stimulation signal with the ventilator breath cycle.
In accordance with a thirtieth embodiment, the controller is further programmed to: monitor the diaphragm output in response to the last administered stimulation signal; and compare the diaphragm output of the last administered stimulation signal to a preselected target range.
In accordance with a thirty-first embodiment, the controller is programmed to monitor the diaphragm output by sensing diaphragm output data via one of said one or more sensors and processing the sensed diaphragm data to determine the diaphragm output, wherein the diaphragm output includes flow, tidal volume and/or pressure and/or parameters derived from combinations of flow, tidal volume and/or pressure.
In accordance with a thirty-second embodiment, the controller is further programmed to modify the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside a preselected range. Alternatively, the signal could be modified and administered at the next breath with programmed pacing (i.e., a combined breath) as some ventilator breaths may be skipped between stimulations.
In accordance with a thirty-third embodiment, the controller is further programmed to determine a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
In accordance with a thirty-fourth embodiment, if the controller determines that the cause is due to a variation in the respiratory mechanics of the patient, then the controller is further programmed to assess the condition of the patient's diaphragm and respiratory system during administration of the treatment plan.
In accordance with a thirty-fifth embodiment, the controller is further programmed to reprogram the stimulation signal based on the condition of the assessed diaphragm.
In accordance with a thirty sixth embodiment, the controller is further programmed to assess the diaphragm by monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay, progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm and respiratory system. In some embodiments, the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
In accordance with a thirty-seventh embodiment, the controller is further programmed to determine the readiness to wean from the ventilator based on the assessment of the diaphragm.
In accordance with a thirty-eighth embodiment, the stimulation signal includes a doublet or triplet pulse at the beginning of the stimulation train or in the middle of the simulation train.
In accordance with another aspect of the present disclosure, a method is provided for preventing respiratory disuse atrophy in a patient who is attached to a mechanical ventilator and receiving artificial breath cycle respiratory assistance and sedation. The method comprises placing a first electrode in the patient's vasculature in proximity to the left phrenic nerve, placing at second electrode in the patient's vasculature in proximity to the right phrenic nerve, and within hours of attaching the patient to the ventilator, delivering a pre-programmed stimulation signal to the first and second electrodes in order to stimulate the diaphragm in synchrony with the ventilator breath cycle.
In accordance with a thirty-ninth embodiment, within hours includes one of the following: within twelve hours; within six hours, within five hours; within four hours, within three hours; and within one hour.
In accordance with a yet another aspect of the present disclosure, a method is provided for administering a treatment plan for preventing or speeding up reversal of diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The ventilator provides a breath cycle to the patient and the patient has a prescribed assist level. The method comprises storing a measurement value indicative of a preselected range of diaphragm output, wherein the diaphragm output is at least a portion of the prescribed assist level, monitoring the breath cycle of the ventilator, administering a stimulation signal to the patient in synchrony with the breath cycle of the ventilator to recruit the diaphragm of the patient, the recruitment of the diaphragm causing a level of diaphragm output, and regulating the diaphragm output of the patient attributable to phrenic recruitment for each stimulated breath cycle in order to fall within the preselected range of diaphragm output.
In accordance with a fortieth embodiment, regulating the diaphragm output of the patient for each breath cycle includes monitoring the diaphragm output in response to the last administered stimulation signal, and comparing the diaphragm output of the last administered stimulation signal to the preselected range of diagram output.
In accordance with a forty-first embodiment, monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, and processing the sensed diaphragm output data to determine the diaphragm output. In some embodiments, the diaphragm output includes one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure.
In accordance with a forty-second embodiment, regulating the diaphragm output of the patient for each breath cycle further includes comparing the determined diaphragm output to the preselected range of diagram output, and modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output from the last administered stimulation signal fell outside of the preselected range of diagram output.
In accordance with a forty-third embodiment, modifying the stimulation signal includes increasing the intensity of the stimulation signal.
In accordance with a forty-fourth embodiment, increasing the intensity includes one or more of: increasing the frequency of stimulation signal pulses; increasing the amplitude of stimulation signal pulses; and/or increasing the duration of stimulation signal pulses.
In accordance with a forty-fifth embodiment, diaphragm output includes tidal volume, pressure, or combinations thereof.
In accordance with a still another aspect of the present disclosure, a method is provided for preventing diaphragm disuse atrophy in a critically ill patient. The method comprises attaching a patient to a ventilator, monitoring the breath cycle of the ventilator; administering, within one of twelve hours or six hours of attaching the patient to the ventilator, a pre-programmed stimulation signal to the patient to recruit the diaphragm of the patient for outputting a level of diaphragm output, and regulating the level of diaphragm output of the patient for each breath cycle based on the administration of the stimulation signal to match or exceed a preselected threshold.
In accordance with yet still another aspect of the present disclosure, a method is provided for constructing a therapy plan for a patient. The therapy plan attempts to prevent disuse atrophy or rehabilitate the patient's diaphragm. The method comprises assessing the diaphragm for maximum diaphragm output and fatigue characteristics, and determining one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
In accordance with a forty-sixth embodiment, the method further comprises creating a stimulation administration plan including a series of discrete stimulation signals, wherein the series of stimulation signals can vary by rate, duration, pulse width, frequency, and amplitude.
In accordance with still yet another aspect of the present disclosure, a method is provided for assessing a diaphragm. The method comprises monitoring data indicative of flow and pressure of a ventilator breath cycle, stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals. In some embodiments, the one or more functional characteristics including one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
In accordance with still another aspect of the present disclosure, a transvascular diaphragm pacing system is provided for constructing a therapy plan for a patient. The therapy plan in some embodiments prevents diaphragm disuse atrophy or rehabilitates the patient's diaphragm. The system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to assess the diaphragm for maximum diaphragm output and fatigue characteristics, and determine one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
In accordance with yet still another embodiment, a transvascular diaphragm pacing system is provided for assessing a diaphragm. The system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from the ventilator and the diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to: monitor data indicative of flow and pressure of a ventilator breath cycle; stimulate the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determine one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals. In some embodiments, the one or more functional characteristics include one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
The foregoing aspects and many of the attendant advantages of the claimed subject matter will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
The detailed description set forth below in connection with the appended drawings where like numerals reference like elements is intended as a description of various embodiments of the disclosed subject matter and is not intended to represent the only embodiments. Each embodiment described in this disclosure is provided merely as an example or illustration and should not be construed as preferred or advantageous over other embodiments. The illustrative examples provided herein are not intended to be exhaustive or to limit the claimed subject matter to the precise forms disclosed.
The following discussion provides examples of transvascular diaphragm pacing systems (TDPS) and methods for providing respiratory therapy to a patient. Some examples of the TDPS provide rapid insertion and deployment of endovascular pacing electrodes in critically ill patients who require intubation and invasive PPMV in order to support the physiological requirements of the human ventilatory system. Examples described herein make best use of the contractile properties of the diaphragm muscle and prevent muscle disuse and muscle atrophy. This can be carried out by engaging the phrenic nerves using patterned functional electrical stimulation applied to endovascular electrodes that are temporarily and reversibly inserted in central veins of the patient, such as the left subclavian vein and the superior vena cava. In some examples, the TDPS is designed to seamlessly interface with any commercially available positive-pressure ventilatory assistance/support equipment such as is commonly in use in hospital intensive care units (ICU) for treating critically ill patients with breathing insufficiencies, pain, trauma, sepsis or neurological diseases or deficits.
Rapid insertion and deployment of the disclosed systems can be effected via employment of minimally invasive central line catheter-based electrodes, such as those described in U.S. application Ser. No. 12/524,571, filed Jul. 25, 2009, which can be quickly installed in the patient under local anesthesia and rapidly activated, such that a pacing therapy can be initiated within one or a few hours of admission/intubation. If indicated by the patient clinical status, pacing via electrical stimulation can proceed in synchrony with ventilator breaths provided by virtually any brand or model of commercially available positive-pressure ventilator operating in typical modes such as Control Mode, Support Mode or Assist Mode. Once therapy is complete, the pacing catheter electrodes can be easily removed. In some embodiments, system pacing follows the operation of a ventilator while in other embodiments, the ventilator initiates and/or assists a breath cycle based on physiological responses generated by the pacing system.
Rapid deployment, i.e., within a few hours of admission/intubation, is advantageous in preventing the ill effects of muscle disuse atrophy, which are known to occur very quickly in ventilated and sedated patients, and to maintain diaphragm muscle strength and endurance during the critical period when a patient is unable to breathe independently.
As will be described in more detail below, the systems of the present disclosure are designed to stimulate the right phrenic nerve (to recruit the right hemi-diaphragm), the left phrenic nerve (to recruit the left hemi-diaphragm), or both phrenic nerves in order to recruit the entire diaphragm muscle. Furthermore, each phrenic nerve may be recruited using a single channel of stimulation or two or more channels of stimulation per nerve. An example showing one embodiment employing two channels of stimulation per phrenic nerve is shown in
In the following description, numerous specific details are set forth in order to provide a thorough understanding of one or more embodiments of the present disclosure. It will be apparent to one skilled in the art, however, that many embodiments of the present disclosure may be practiced without some or all of the specific details. In some instances, well-known process steps have not been described in detail in order not to unnecessarily obscure various aspects of the present disclosure. Further, it will be appreciated that embodiments of the present disclosure may employ any combination of features described herein.
Turning now to
As will be described in more detail below, the parameters (amplitude, duration, frequency, etc.) of stimulation pulses affect the amount of diaphragm recruitment, and the resulting output (such as tidal volume, pressure) therefrom. In that regard, and as will be described in more detail below, sensors 48 configured to sense various physiological parameters of the patient, some indicating diaphragm output, can provide feedback to the stimulator 24 for regulation of the administered therapy.
As described herein, the system 20 can be the sole respiratory aid for the patient. In other embodiments, the system 20 operates in conjunction with a positive pressure mechanical ventilator 32 (“ventilator 32”) in order to satisfy the respiratory needs of the patient. In some embodiments, signals sensed from a breath sensor 50 that monitors the breath cycle of the ventilator 32 can be employed to synchronize the delivery of the stimulation signals with the ventilator breath cycle.
The respiratory needs of the patient are sometimes referred to as the patient's prescribed assist level. The prescribed assist level is generally quantified as the amount of tidal volume or pressure (or a combination of the two) provided to the patient during one breath cycle that satisfies the minimum physiological functions of the patient. Generally, the prescribed assist level in terms of tidal volume is approximately 7-10 mL per Kg of patient weight. In some embodiments, the prescribed assist level is satisfied solely via artificial means (e.g., via system 20, via ventilator 32, or a combination of the two). This may occur in patients that are heavily sedated and/or unconscious. In other embodiments, the prescribed assist level may include some patient initiated respiratory effort.
As will be described below, in some embodiments, the clinician, as part of a therapy plan, can program the system 20 in order to satisfy the prescribed assist level (i.e., in tidal volume, pressure, or both) via recruitment of the diaphragm. In other embodiments, the clinician can program the system 20 to contribute only a percentage of the prescribed assist level (in volume, pressure, or both), referred to herein as the diaphragm contribution or diaphragm contribution level, via electrical recruitment of the phrenic nerve or nerves. The percentage can vary, and is patient-dependent based on a variety of factors, such as the condition of the patient, the ailment afflicting the patient, time elapsed preceding any stimulation therapy, etc. In this embodiment, the remaining percentage of the prescribed assist level can then be satisfied by the ventilator 32, which can be appropriately programmed by the clinician at the onset of or during administration of the therapy plan.
In some embodiments, as will be described in more detail below, the system 20 carries out one or more assessments of the patient in order to determine, for example, the current condition of the patient's diaphragm, the stimulation signal characteristics that relate to the recruitment of the diaphragm, such as threshold pulse width, pulse amplitude, pulse frequency, sub-maximal pulse width, and supra-maximal pulse width, etc. Threshold Pulse Width refers to a minimum pulse width at and above which there is a diaphragmatic response. Threshold Frequency refers to a minimum frequency at and above which partly or completely fused Tetanic contractions are produced, so as to generate useful diaphragmatic force and/or work.
Turning now to
Turning now to
The system 20 further includes a third electrode 28C having anodal and cathodal electrode contacts 30C, 32C placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve. In the embodiment shown, a fourth electrode 28D having anodal and cathodal electrode contacts 30D, 32D may be also placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve.
While two electrodes are shown and described for stimulating each of the left and right phrenic nerves, it will be appreciated that other numbers of electrodes may be practiced with embodiments of the present disclosure. For example, four electrodes can be used for stimulating each phrenic nerve. For more information regarding the placement of a plurality of electrodes endovascularly as well as the configuration of one type of electrode structure that can be practiced with embodiments of the present disclosure, please see U.S. application Ser. No. 12/524,571, filed Jul. 25, 2009, the disclosure of which is hereby expressly incorporated in its entirety. Additionally, while electrodes with anodal and cathodal electrode contacts are utilized to emit the stimulation pulses into the phrenic nerves, other configurations are possible. For example, several cathodal electrode contacts may be used in conjunction with a single anodal electrode contact, and vice versa.
Each electrode 28 is connected in electrical communication with the stimulator 24. In the embodiment shown, each electrode 28 is electrically connected to the stimulator 24 via lead(s) 40.
The system 20 further includes one or more sensors 48 configured to monitor the response to phrenic nerve stimulation and/or other physiological characteristics of the patient. As will be described in more detail below, the one or more sensors 48 can be part of a feedback control scheme for regulating the stimulation administered to the patient. The plurality of sensors 48 can transmit data to the stimulator 24 indicative of one or more of the following: electromyographic activity (intramuscular, surface, and/or intraesophageally monitored), central venous pressure (any specific component of this signal), heart rate, chest wall acceleration, blood oxygen saturation, carbon dioxide concentration, catheter position/depth within vein, mechanical movement (i.e., from accelerometers, length gauges, and/or strain gauges) resistance (i.e., from impedance pneumographs, and/or piezoresistive sensors) and/or other physiological or mechanical parameters. It will be appreciated that the information can be appropriately processed (e.g., filtered, conditioned, amplified, etc.) prior to use by the stimulator 24.
The term “volume” as used herein includes, but is not limited to, Inspired Tidal Volume, Expired Tidal Volume or Minute Volume. The term “pressure” as used herein includes, but is not limited to, Airway Pressure, Alveolar Pressure, Ventilator Pressure, Esophageal Pressure, Gastric Pressure, Transdiaphragmatic Pressure, Intra-Thoracic Pressure Positive End-Expiratory Pressure or Pleural Pressure. Any pressure may be Peak Pressure, Mean Pressure or Baseline Pressure. The term “flow” as used herein includes, but is not limited to, Inspiratory Flow or Expiratory Flow.
In some embodiments, the electrodes 28 can also monitor physiological variables of the subject by virtue of their placement in the central veins. Such monitored physiological variables can include, but are not limited to: central venous pressure, electrocardiogram, and mixed venous oxygen saturation. It will be appreciated that one or more sensors discrete from the electrodes, such as one or more of the sensors 48, may be used to monitor such physiological variables.
In some embodiments, the system 20 can additionally or alternatively include a breath sensor 50 for sensing parameters of the ventilator 32. In that regard, the breath sensor 50 can be configured to interface with any standard breathing circuit used in critical care ventilators and therefore the pacing system is independent of the brand of ventilator used. The breath sensor 50, by virtue of its location in the breathing circuit, can monitor and/or measure several ventilation parameters and communicate such parameters to the stimulator 24. As will be described in more detail below, the breath sensor 50 can be part of or used solely as a feedback control scheme for regulating the stimulation administered to the patient. The sensed ventilation parameters may include, but not limited to, airflow (inspired and/or expired), volume, pressure (airway, esophageal, gastric, and/or some combination/derivative of the former). In some embodiments, other sensors may aid in the procurement of one or more ventilation parameters.
In some embodiments, the example parameters are being measured both to and from the ventilator 32. In the embodiment shown, the breath sensor 50 is external to the ventilator 32 so that the system is independent of ventilator model. However, the system 20 could also be integrated to use a ventilator's internal sensors or signals externally supplied by the ventilator can provide the information to the system 20 for proper operation so that an external breath sensor can be omitted.
The stimulator 24 functions, in part, as a signal generator for providing therapy to the diaphragm in response to information received from the one or more of the sensors 48 and 50 and/or information programmed into the system 20 by the clinician. In that regard, the stimulator 24 delivers pulses to the endovascular electrodes 28 in accordance with one or more protocols described herein. As will be described in more detail below, the pulses in some embodiments are generated by the stimulator 24 with characteristics that deliver a suitable charge to the phrenic nerves in order to provide enough diaphragm recruitment to satisfy the selected diaphragm contribution (e.g., in volume, pressure, both, or derived parameters from volume and pressure) of the prescribed assist level described above.
Towards that end, the stimulator 24 is configured to deliver fully programmable stimulation, including, but not limited to, the following: any number of pulses, any combination of the defined pulses, any order of delivery of the defined pulses, multiple instances of any defined pulse(s), any frequency of stimulation, and/or any delay between pulses (interpulse delay). Each pulse can be independently programmable (e.g., frequency, amplitude, duration, etc.). The stimulation pulse(s) and/or train(s) may or may not generate a repeatable pattern.
Each pulse includes a charge injection phase and a charge balance phase (biphasic). In some embodiments, the balance phase duration and amplitude is programmable as a ratio of the charge phase duration and amplitude so that zero net charge is maintained, as shown in
Because the diaphragm is skeletal muscle, pacing may be accomplished by delivering one or more stimulation signals to produce a mechanically effective contraction of the diaphragm. In that regard, the stimulation signals may include a plurality of pulses that are grouped in stimulation trains. As used herein, a stimulation train is defined as a collection of stimulation pulses. This definition does not imply a specific composition, order of delivery, and/or shape profile or envelope.
Stimulation or pulse trains are typically characterized by the rate, the duration, the pulse width, the frequency, and the amplitude of the signals. The rate of the stimulation train corresponds to the number of stimulation trains delivered per minute, which can correlate with the patient's respiratory rate or mechanical ventilator rate. The duration of the stimulation train refers to the length of time the stimulation train is delivered. The pulse width indicates the duration of each individual pulse creating the stimulation train. Similarly, the frequency indicates the number of individual pulses delivered per second. Finally, the amplitude refers to the voltage of each pulse delivered. The parameters of amplitude, frequency, and pulse width determine the strength of the induced diaphragmatic pacing.
In some embodiments, the stimulation trains form ramp trains. For example, ramp trains can be formed by linearly increasing (or decreasing) either the instantaneous frequency of consecutive pulses in a train, the durations (pulse widths) of consecutive pulses in a train, or both. Ramp trains indicate that a change in injected charge is induced by the programmed stimulation parameters and any applied modulation.
Variations in pulse width and frequency modulation allow different ramp train envelopes to be designed. Referring to
Although a large set of ramp trains can be generated, there will be some embodiments where the ramp trains aim to achieve one or more of the following: 1) mimic physiological contraction of the diaphragm by independently controlling recruitment and rate coding by means of pulse width and frequency modulation, respectively; 2) delay the onset of neuromuscular fatigue; 3) maintain the native fiber composition of the healthy diaphragm; 4) condition the diaphragm towards a specific fiber type, for e.g. Type I (Slow Twitch, Fatigue Resistant).
With the various programmable stimulation trains or ramp trains, a therapy plan can be constructed by the clinician with or with the aid of the system 20. The therapy plan constructed by the clinician is patient dependent in order to achieve various goals. The therapy plan may include one or more of the following: timing of delivery of pacing in relation to ventilator breaths (e.g., every breath, every other breath, every five breaths, etc.); intermittent stimulation segments (e.g., stimulation delivery for 15 minutes every hour), etc. As an example, in a patient who requires PPMV and sedation, a therapy plan would take into consideration both major objectives of minimizing VIDD and minimizing risk of VILI. As another example, in a therapy plan for a patient who able to remain awake during part of the day and breathe independently for some hours and will soon be attempting to wean, it may be desirable to not pace while the patient is breathing spontaneously but, conversely, to pace at a low assistive level during the night while the patient is again sedated and placed back on PPMV, in order to reduce the peak pressure required for ventilation and thus reduce risk of VILI.
In some embodiments, the therapy plan includes the ability to skip stimulation, sometimes referred to as skipped breaths, which allows for a ventilator breath to be delivered without being accompanied by stimulation from the system 20. Additionally or alternatively, the therapy plan may include sigh breaths. Sigh breaths are characterized as intermittently programmable breaths that inject more charge than a normal breath (i.e. a higher magnitude stimulation train). Physiologically, this results in a more forceful contraction of the diaphragm. Both functions are programmable independently and can be repeatable. For sigh breaths only, the percentage increase in amplitude is programmable based on the amplitude of a typical paced breath. It is possible to implement these features independently or combined.
The stimulator 24 in some embodiments is configured to generate constant-amplitude current pulses with pulse duration in the range from 50-300 microsec, controllable in increments of 10 microsec. The amplitude and duration of each pulse in a train can be independently programmed. The amplitude of pulses can be selected between 0.1 and 10 mA in 0.1 mA increments. The main parameter that determines whether a stimulus pulse will be sufficient to activate a nerve axon (reach its threshold to fire an action potential) is the charge delivered by the stimulus, where charge (in nC)=pulse current amplitude (in mA)×pulse duration (in microsec). In this regard, the stimulator 24 can produce pulses in the range from 5 nC to 3000 nC and the charge per pulse can be specified in increments of 1 nC.
Those skilled in the art and others will recognize that the controller 60 serves as the computational center of the stimulator 24 for carrying out logic or by supporting the execution of routines, instructions, etc., for providing functionality to the stimulator 24. In that regard, the logic, routines, instructions, etc., described herein may be implemented in hardware, in software, or a combination of hardware and software.
In some embodiments, the controller 60 includes one or more processors and memory. The logic, routines, instructions, etc., may include a set of control algorithms, including resident program instructions and calibrations stored, for example, in the memory and executed to provide a desired functionality of the system 20. The algorithms may be executed during preset loop cycles such that each algorithm is executed at least once each loop cycle. Algorithms stored in non-volatile storage medium can be executed by the processor to: 1) monitor inputs from the sensors 48, 50 and other data transmitting devices or polls such devices for data to be used therein; 2) cause the pulse generator to generate and transmit one or more pulses to the electrodes 28; and 3) regulate the diaphragm output of the patient, among other functions. Loop cycles are executed at regular intervals, for example each 3.125, 6.25, 12.5, 25 and 100 milliseconds during ongoing operation of the system 20. Alternatively, algorithms may be executed in response to the occurrence of an event.
As used herein, the term processor is not limited to integrated circuits referred to in the art as a computer, but broadly refers to a microcontroller, a microcomputer, a microprocessor, a programmable logic controller, an application specific integrated circuit, other programmable circuits, such as programmable gate arrays, combinations of the above, among others. In some embodiments, the controller 60 may include additional components including but not limited to a high speed clock, analog to digital (A/D) and digital to analog (D/A) circuitry, input/output circuitry and devices (I/O) and appropriate signal conditioning and buffer circuitry.
It will be appreciated that the signals received from the sensors 48, 50 may be processed by an optional signal processing section 80 prior to arriving at the controller 60. For example, the signal processing section 80 may include dedicated circuits, processors, such as digital signal processors (DSP), etc., for receiving, processing and filtering electrical signals sensed by the sensors associated with the subject and/or the ventilator 32. Signal processing section 80 can include amplifiers and circuits to condition, filter and/or amplify the electrical signals supplied thereto. In some embodiments, the signal processing section 80 carries out discrete tasks, such as the determination of one or more physiological states. One physiological state that can be determined by signal processing section 80 is a patient's minute volume or ventilation. Minute ventilation is a respiratory related parameter that is a measure of the volume of air inhaled and exhaled during a particular period of time. The minute ventilation is the product of respiration rate and tidal volume. Signal processing section 80 can also be used to receive and process signals representing other respiratory activity such as intrathoracic pressure, chest wall motion, etc. Of course, the determination of one or more physiological states, processing of signals, implementation of logic or processes, etc., can be carried out solely by the controller 60.
Still referring to
In accordance with aspects of the present disclosure, one or more embodiments of the system 20 can be operated in various pacing modes. The pacing modes may be alternatively employed by a clinician, depending on the clinical status and needs of each patient and on the operational properties of a ventilator, such as ventilator 32, which may be available in a particular ICU. The pacing modes can include but are not limited to Ventilator-Initiated Pacing Mode, Pacer-Initiated Ventilation Mode, and Autonomous Pacing Mode. Those skilled in the art will understand that these modes may be engaged in many ways to generate different combinations of system functionality, but for reasons of brevity all possible combinations are not listed herein. Each of these modes will now be described in some detail.
The first mode of the system 20 to be described herein is the Ventilator Initiated Pacing Mode. As will be described in more detail below, this mode operates the stimulator 24 in synchrony with the operation of the ventilator 32. This mode can work with any mechanical ventilator in control mode, whereby the flow or pressure is controlled by the ventilator and delivered at a pre-determined frequency (breath rate). Delivery of stimulation ramp trains generated by the stimulator 24, such as any of those shown in
Turning now to
As shown in
In some embodiments, the clinician can input the prescribed assist level for the patient depending upon clinical status. The prescribed assist level in some embodiments is programmed as tidal volume. Alternatively, it can also be programmed as: (1) a desired amount of pressure generated by the diaphragm; (2) the product of pressure and volume, referred to as Work of Breathing (WOB) shown in
Along with the diaphragm contribution level, the clinician can program the system 20 with one or more stimulation parameters, such as amplitude, duration, frequency, etc., that are capable of recruiting the diaphragm in order to satisfy the diaphragm contribution level (e.g., in volume or pressure, or both). In other embodiments, as will be described in detail below, some of the stimulation parameters which correspond to the diaphragm contribution level, may have been previously programmed into or obtained by the system 20.
The clinician may also enter the amount of therapy to be provided per 24 hour period. For example, the clinician may wish to administer therapy for eight (8) hours out of each 24 hour period. The therapy can be administered consecutively for 8 hours, or can be segmented into time period blocks (e.g., 2 hrs., 1 hr., 30 minutes, 15 minutes, etc.), which can be either constant or variable. If variable, the time period blocks can form a repeatable pattern, if desired. The therapy may also vary the diaphragm contribution throughout the period of administered stimulation. In some embodiments, the clinician can program sigh breaths or skipped breaths, as described above with reference to
Returning to
Next, at block 106, synchrony between the ventilator 32 and the administration of pacing therapy is maintained. This ensures that diaphragm pacing by stimulation signals emitted by the electrodes is synchronized with each breath administered by the ventilator 32. If an uncoupling is suspected, pacing may be skipped and resumed as soon as the ventilatory pattern stabilizes again. In other embodiments, the pacing can continue while synchrony is reestablished. In some embodiments, synchrony is determined by comparing the attributes of at least one previous breath cycle (e.g., 12 breaths per minute, etc.) with the attributes of the current breath cycle of the ventilator 32 as determined via processing of the signals from the breath sensor 50 and/or one or more of the sensors 48.
From block 106, the routine proceeds to block 108. At block 108, the diaphragm output (e.g., tidal volume, pressure, or a combination of the two) is regulated to ensure the programmed prescribed assist level is satisfied. In this regard, in some embodiments, the system 20 monitors the data from one or more of the sensors 48 and/or sensor 50 for determining the diaphragm contribution (tidal volume, pressure, or both) for each ventilator breath. This may be calculated from the measured output (i.e., the sum of diaphragm contribution and ventilator contribution) of each ventilator breath or can be calculated directly from the sensor data. If the diaphragm output (or diaphragm contribution) from the previous administered stimulation signal is within a preselected range, the programmed stimulation parameters are maintained, and will be subsequently employed to generate the stimulation train for therapy administration at the next breath.
If the calculated diaphragm contribution resulting from the last administered stimulation signal differs from the target diaphragm contribution value by more than a preselected amount, the stimulation parameters may be modified (e.g., amplitude and/or duration are increased) so as to maintain the diaphragm output within a desired range. Such a difference between the calculated diaphragm contribution responsive to the last administered stimulation signal and the programmed diaphragm contribution value can be seen as a change in either the pressure (in Volume-Controlled Modes/Ventilators) or as a change in tidal volume (in Pressure-Controlled Modes/Ventilators) or as a change in any signal sensed by one or more of the sensor(s) 48 or sensor 50. The modified stimulation parameters are then stored in memory. In some embodiments, the system 20 operates in accordance with a “closed-loop” feedback scheme to regulate the diaphragm output during operation of the system 20, one example of which is shown in
In some embodiments, an evaluation is carried out to determine the reason for such a drop in tidal volume or pressure. For example, in some embodiments, the discrepancy in reaching the diaphragm contribution target may be due to a displacement of a stimulation electrode away from an optimal position. In other embodiments, the discrepancy or variability in tidal volume or pressure between breaths can be attributable to either changing respiratory mechanics of the patient or to time-dependent fatigue of the higher force producing fast-fatigable (Type IIb) fibers.
Changes in respiratory mechanics may include changes in airway resistance and/or compliance of the lungs/chest wall. For example, in the embodiment shown in
In the 4th breath shown in
It will be appreciated that similar principles can be applied to a pressure controlled ventilator, where changes in respiratory mechanics may be indicated by changes in tidal volume between breaths. The system 20 may be configured to adaptively modify the pacing parameters to return the tidal volume to the prescribed assist level.
As described above, the discrepancy or variability in tidal volume or pressure between breaths can be also attributable to time-dependent fatigue of the higher force producing fast-fatigable (Type IIb) fibers. For example,
As shown in
The force declines again as the Type IIb Motor Units present in the newly activated cross-section of the phrenic nerves, fatigue in turn. At this point the pacing intensity is increased again by the pacing control system in order to activate an even larger cross-sectional area of the phrenic nerve, recruiting more Motor Units to reestablish the force output. This progressively increasing activation of the phrenic nerve continues and finally up to 100% of the phrenic nerve motor units may be recruited. Eventually all the Type IIb Motor Units are knocked out by fatigue and only the Type I and Type IIa Motor Units continue to contribute force.
It will be appreciated that the increase in the stimulation may be a simple linear equation or a complex equation with weights assigned to the proportion of available fibers and their fatigue resistant properties. The loss of force may be attributed specifically to the fatigue of the fast fatigable fibers, using parameters such as Maximum Relaxation Rate and half-relaxation time. The changes in slope of the first half of the diaphragm relaxation curve indicative of the relative contribution of Type I and Type II fibers to force development may also be used. Other parameters specific to fatigue such as Pressure-Time Index, Expiratory Time Constant, EMG (and any derived parameters thereof such as power spectrum), Ratio between slow and fast twitch amplitudes, may also be employed to infer the varying conditions and to determine the modified stimulation parameters.
In another embodiment, the closed-loop control strategy may include using doublets/triplets in response to contractile slowing accompanying fatigue of the diaphragm Motor Units. When fatigue is detected by the system 20, the stimulation pattern is automatically changed to include doublet/triplets and otherwise lower stimulation frequency, as this form of stimulation is known in the art to optimize force production in fatiguing/fatigued motor units. Once the fatigued motor units have recovered their strength, the stimulation pattern can again be changed to moderate stimulation frequency with or without doublets. This closed-loop scheme allows for continuous pacing of the diaphragm irrespective of the onset or progression of fatigue, also reduces the number of stimulation pulses delivered and protects the muscle from potential injury that could be caused by over-stimulation.
Returning to
For example, depending on the ventilator mode, the system 20 can trigger off pressure or airflow signals. Once the inspiration/expiration phases have been determined, such as in block 104, to stimulate during the inspiration phase, the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in
Once timing is determined, the routine at block 110 delivers the stimulation pulses to the stimulating electrodes 28 at the appropriate time for transmission therefrom. The routine returns to block 104 until the time period for therapy has expired or a clinician halts operation of the system 20.
In some embodiments, the system 20 may assist the clinician in determining the appropriate level of diaphragm contribution to be input into the system 20. In that regard, the diaphragm contribution can be dependent on the condition of the patient's diaphragm. For example, in a patient that has only a maximum diaphragm output of 750 mL and the clinician intends to target an assist level of 500 mL, the clinician may unknowingly choose a diaphragm contribution level that would require delivery of the maximum stimulation charge, which will cause premature fatigue, etc. Given this patient's present diaphragm condition, the clinician may wish to choose a much lower percentage so that the stimulation charge is in-between the threshold charge and the supra-maximal charge.
Thus, in some embodiments, in order to appropriately select the diaphragm contribution level, the condition of the diaphragm and the respiratory system is first assessed by the system 20. In that regard, the system 20 is configured to run one or more assessments on the patient's diaphragm and/or respiratory mechanics. The assessment determines the maximum diaphragm output (in volume, pressure, or both) and other parameters such as the fatigue characteristics of the diaphragm, the resistance, compliance and relaxation characteristics of the respiratory system and its components, etc. The assessment can be also run in-between or during periods of the operation of the system 20 in synchrony with the ventilator 32. These tests can either be run by shortly disconnecting the patient from the ventilator 32 and pacing the diaphragm in isolation or can be run with the patient connected to the ventilator 32 by employing a sequence of pauses in the operation of the ventilator 32 during which the diaphragm is paced in isolation. The sequence of pauses may either be employed manually by the clinician, or natural pauses that are part of a regular ventilator breath cycle (such as an End-Inspiratory Pause or an End-Expiratory Pause) may be automatically identified and used by the system 20.
Generally described, after the flow of gas from the ventilator 32 is momentarily occluded, the maximal static pressures generated by the diaphragm in response to supramaximally stimulating the phrenic nerves to elicit twitch, ramp, or tetanic contractions of the diaphragm are measured as well as the diaphragm relaxation characteristics during the inspiration and expiration phases. The assessment can pace the diaphragm in isolation with a preset duty cycle to assess diaphragm function with regard to its strength and endurance properties. From the data sensed by one or more sensors 48 and/or the sensor 50, measures and/or indices can be derived that include, but are not limited to, Maximum Static/Dynamic Inspiratory Pressures, Inspiratory Capacity, Pressure-Volume loop relationships, Work of Breathing. Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant. Diaphragm fatigue can be induced by continuous or intermittent stimulation of the phrenic nerves to assess endurance limits and to detect the presence of low frequency and/or high frequency fatigue. As the normal values for most of the calculated or derived parameters have a wide normal range, serial measurements set apart in time ranging from a few minutes to days, can be done on a patient by the pacing system to provide a complete picture of evolving changes in the diaphragm strength and endurance of the patient.
In some embodiments, a knowledge-based algorithm may be used to monitor instantaneous and/or trend data of the monitored signals. Such instantaneous and/or trend data may allow the assessment to predict weaning readiness of the patient and/or a time course for weaning. Such capability can also be extended to make the diaphragm assessment tests as a standalone screening and/or confirmatory tool by clinicians in the ICU, as the method of transvascular pacing of the diaphragm enables the clinician to assess the true status of the diaphragm in the absence of confounding factors (such as decreased central drive) usually associated with voluntary breathing maneuvers.
Once the maximum diaphragm output is determined, the diaphragm contribution level can be chosen with knowledge of the relationship between the prescribed assist level and the maximum diaphragm output. In order to understand this relationship, the controller 60 in some embodiments, via one or more subroutines, can recursively estimate the percentage of maximum diaphragm output required to generate 100% of the prescribed assist level. Of course, this and other calculations can be made on a separate computer system and imported or otherwise inputted into the controller 60 prior to operation of the system 20. One example of this recursive estimate is shown in
In some embodiments, and described generally above, the clinician has the option to adjust the diaphragm contribution during operation of the system 20 from 0 to 100% of the prescribed assist level, as illustrated by the dial of
In some embodiments, the condition of the diaphragm is periodically reassessed after the therapy has been administered for a period of time (e.g. 12 hours, 1 day, etc.). For example, as described briefly above with regard to the closed-loop control method for regulating the diaphragm output, the variability in volume or pressure between breaths in some instances is attributable to changing respiratory mechanics of the patient, including changes to airway resistance and/or compliance of the lungs/chest wall. In other embodiments, the diaphragm muscle, through the administration of the therapy, has strengthened, and thus, the diaphragm contribution can be increased or the intensity of stimulation can be decreased to adjust the diaphragm contribution. In these cases, it may be beneficial to periodically reassess the diaphragm and optimize pacing therapy accordingly, after therapy has been initiated.
One example of a routine for measuring changes in the diaphragm condition without removing the patient from the ventilator 32 is shown in
As best shown in
Depending on the ventilator mode, the system 20 can trigger off pressure or airflow signals. Once the inspiration/expiration phases have been determined, to stimulate during the inspiration phase, the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in
Flow, volume, and/or pressure data, or derived parameters thereof, for at least one breath with stimulation is recorded. For the data with stimulation as well as without, if more than one breath of information has been recorded the data can be averaged together. The collected flow/volume/pressure data with stimulation is then subtracted from the collected flow/volume/pressure data without stimulation. The difference, calculated as an area (and shown as the blacked-out area), can be used as a relative measurement of force generated by the diaphragm, and is shown in
As exemplified in
This period of zero volume can be determined prior to stimulation to determine the duration of the end-expiratory pause. In that regard,
While using volume data in some embodiments is one technique, this does not preclude using other measures of the end expiratory phase such as a slope close to zero or simply using a fixed time interval at the end of the expiration phase as the end expiratory pause. In other embodiments, the system 20 can compute relaxation characteristics of the respiratory system, such as Expiratory-Time Constant (i.e. time required to exhale a certain percentage of the air from the lungs) to determine the ideal end-expiratory pause duration and prompt the clinician to adjust the ventilator settings accordingly. At any point in the assessment, the user has the ability to manually override the system and select the duration of the end-expiratory pause as a percentage or absolute value of the measured expiratory phase duration.
Returning to
Next, at block 304, the breath detection algorithm described above can be employed to synchronize the administered stimulation with the end-expiratory pause period of the ventilator 32. For example, the breath detection algorithm can be employed to identify the period of interest during a breath cycle when stimulation can be delivered, as shown in
At block 306, based on the aforementioned monitored parameters, a determination is made as to whether the patient's lungs have returned to Functional Residual Capacity as the ventilator carries out the breath cycle. When it is determined that the Functional Residual Capacity is reached, the system 20 administers a starting stimulation signal at block 308 and then monitors and measures the diaphragm response to the administered stimulation at block 310. Signals that can be monitored and measured to quantify the diaphragm response may include, but are not limited to, EMG, Airway Pressure, Airway Flow, Intra-Thoracic Pressure, Pleural Pressure, Central Venous Pressure, Thoraco-abdominal motion, various patient impedances, etc.
Next, a determination is made at block 312 as to whether the next ventilator breath is about to begin. Estimated end expiratory pause duration and/or the monitored signals from sensors 48, 50, can aid in this determination. If not, the routine 300 increases the intensity of the stimulation at block 314 and returns to block 308 to administer the increased intensity pulse. If the next ventilator breath is about to begin, stimulation for the current breath is stopped at block 316, the intensity of the current stimulation level can be increased at block 318, and the routine returns to block 304 for another stimulation to be administered in synchrony with the breath cycle. The routine 300 can continue to loop in some embodiments until either the preset range of stimulation intensities has been reached or the maximum stimulation level has been reached.
As the Functional Residual Capacity can change with time, due to factors such as Extrinsic PEEP or Intrinsic PEEP, the system can also employ validation checks to confirm that the functional residual capacity (and therefore the diaphragm resting length) has not changed between breaths. One of the means to perform this validation is to analyze the trend data of the end-expiratory volume, before stimulating the diaphragm.
The next mode of operation that can be carried out by embodiments of the system 20 includes a Pacer-Initiated Ventilation Mode.
In the Pacer-Initiated Ventilation mode, the system 20 can use feedback to ensure proper diaphragm contribution. Some ventilator modes suitable for this embodiment are Pressure Support Ventilation (PSV), Pressure Regulated Volume Control (PRVC), Proportional Assist Ventilation (PAV) and Adaptive Support Ventilation (ASV).
Embodiments of the system 20 can also be operated in Autonomous Mode, or A-Mode. A-Mode is a life-sustaining mode that can operate independently of the ventilator 32.
Although A-mode can be a life-sustaining mode, it may or may not be used in this capacity (i.e. could be interfaced with a backup ventilator). For example, A-Mode may be applicable to patients who are permanently dependent on mechanical ventilators or otherwise in need of continuous pacing from the system 20.
As opposed the embodiments of the system 20 described above for carrying out the Pacer-Initiated Ventilation Mode and the Ventilator-Initiated Pacing Mode, embodiments of the system 20 carrying out the A-Mode can be totally implanted under the skin of the patient in the upper chest area. In this regard, the system 20 is powered by a power storage source, such as either primary or rechargeable implantable batteries, and may be integrated with other implantable devices that support heart or other functions to a patient.
As shown in the embodiment of
The principles, representative embodiments, and modes of operation of the present disclosure have been described in the foregoing description. However, aspects of the present disclosure which are intended to be protected are not to be construed as limited to the particular embodiments disclosed. Further, the embodiments described herein are to be regarded as illustrative rather than restrictive.It will be appreciated that variations and changes may be made by others, and equivalents employed, without departing from the spirit of the present disclosure. Accordingly, it is expressly intended that all such variations, changes, and equivalents fall within the spirit and scope of the present disclosure, as claimed.
This application is a continuation of U.S. application Ser. No. 14/410,022, filed Dec. 19, 2014, which is a National Stage filing under 35 U.S.C. § 371 of International Application No. PCT/CA2013/000594, filed Jun. 21, 2013, which claims the benefit of U.S. Provisional Application No. 61/662,579, filed Jun. 21, 2012. Each of the disclosures of the above applications is expressly incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
1693734 | Waggoner | Dec 1928 | A |
2532788 | Sarnoff | Dec 1950 | A |
2664880 | Wales, Jr. | Jan 1954 | A |
3348548 | Chardack | Oct 1967 | A |
3470876 | John | Oct 1969 | A |
3769984 | Muench | Nov 1973 | A |
3804098 | Friedman | Apr 1974 | A |
3817241 | Grausz | Jun 1974 | A |
3835864 | Rasor et al. | Sep 1974 | A |
3847157 | Caillouette et al. | Nov 1974 | A |
3851641 | Toole et al. | Dec 1974 | A |
3896373 | Zelby | Jul 1975 | A |
3938502 | Bom | Feb 1976 | A |
3983881 | Wickham | Oct 1976 | A |
4054881 | Raab | Oct 1977 | A |
4072146 | Howes | Feb 1978 | A |
4114601 | Abels | Sep 1978 | A |
4173228 | Childress et al. | Nov 1979 | A |
4249539 | Mezrich et al. | Feb 1981 | A |
4317078 | Weed et al. | Feb 1982 | A |
4380237 | Newbower | Apr 1983 | A |
4407294 | Vilkomerson | Oct 1983 | A |
4416289 | Bresler | Nov 1983 | A |
4431005 | McCormick | Feb 1984 | A |
4431006 | Trimmer et al. | Feb 1984 | A |
4445501 | Bresler | May 1984 | A |
RE31873 | Howes | Apr 1985 | E |
4573481 | Bullara | Mar 1986 | A |
4586923 | Gould et al. | May 1986 | A |
4587975 | Salo et al. | May 1986 | A |
4643201 | Stokes | Feb 1987 | A |
4674518 | Salo | Jun 1987 | A |
4681117 | Brodman et al. | Jul 1987 | A |
4683890 | Hewson | Aug 1987 | A |
4697595 | Breyer et al. | Oct 1987 | A |
4706681 | Breyer et al. | Nov 1987 | A |
4771788 | Millar | Sep 1988 | A |
4819662 | Heil, Jr. et al. | Apr 1989 | A |
4827935 | Geddes et al. | May 1989 | A |
4830008 | Meer | May 1989 | A |
4840182 | Carlson | Jun 1989 | A |
4852580 | Wood | Aug 1989 | A |
4860769 | Fogarty et al. | Aug 1989 | A |
4905698 | Strohl, Jr. et al. | Mar 1990 | A |
4911174 | Pederson et al. | Mar 1990 | A |
4934049 | Kiekhafer et al. | Jun 1990 | A |
4944088 | Doan et al. | Jul 1990 | A |
4951682 | Petre | Aug 1990 | A |
4957110 | Vogel et al. | Sep 1990 | A |
4989617 | Memberg et al. | Feb 1991 | A |
5005587 | Scott | Apr 1991 | A |
5036848 | Hewson | Aug 1991 | A |
5042143 | Holleman et al. | Aug 1991 | A |
5056519 | Vince | Oct 1991 | A |
5115818 | Holleman et al. | May 1992 | A |
5146918 | Kallok et al. | Sep 1992 | A |
5170802 | Mehra | Dec 1992 | A |
5184621 | Vogel et al. | Feb 1993 | A |
5224491 | Mehra | Jul 1993 | A |
5243995 | Maier | Sep 1993 | A |
5265604 | Vince | Nov 1993 | A |
5267569 | Lienhard | Dec 1993 | A |
5314463 | Camps et al. | May 1994 | A |
5316009 | Yamada | May 1994 | A |
5324322 | Grill, Jr. et al. | Jun 1994 | A |
5330522 | Kreyenhagen | Jul 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5383923 | Webster, Jr. | Jan 1995 | A |
5411025 | Webster, Jr. | May 1995 | A |
5417208 | Winkler | May 1995 | A |
5451206 | Young | Sep 1995 | A |
5456254 | Pietroski et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5476498 | Ayers | Dec 1995 | A |
5486159 | Mahurkar | Jan 1996 | A |
5507725 | Savage et al. | Apr 1996 | A |
5524632 | Stein et al. | Jun 1996 | A |
5527358 | Mehmanesh et al. | Jun 1996 | A |
5531686 | Lundquist et al. | Jul 1996 | A |
5549655 | Erickson | Aug 1996 | A |
5555618 | Winkler | Sep 1996 | A |
5567724 | Kelleher et al. | Oct 1996 | A |
5584873 | Shoberg et al. | Dec 1996 | A |
5604231 | Smith et al. | Feb 1997 | A |
5665103 | Lafontaine et al. | Sep 1997 | A |
5678535 | Dimarco | Oct 1997 | A |
5683370 | Luther et al. | Nov 1997 | A |
5709853 | Iino et al. | Jan 1998 | A |
5716392 | Bourgeois et al. | Feb 1998 | A |
5733255 | Dinh et al. | Mar 1998 | A |
5755765 | Hyde et al. | May 1998 | A |
5776111 | Tesio | Jul 1998 | A |
5779732 | Amundson | Jul 1998 | A |
5782828 | Chen et al. | Jul 1998 | A |
5785706 | Bednarek | Jul 1998 | A |
5788681 | Weaver et al. | Aug 1998 | A |
5813399 | Isaza et al. | Sep 1998 | A |
5814086 | Hirschberg et al. | Sep 1998 | A |
RE35924 | Winkler | Oct 1998 | E |
5824027 | Hoffer et al. | Oct 1998 | A |
5827192 | Gopakumaran et al. | Oct 1998 | A |
5916163 | Panescu et al. | Jun 1999 | A |
5944022 | Nardella et al. | Aug 1999 | A |
5954761 | Machek et al. | Sep 1999 | A |
5967978 | Littmann et al. | Oct 1999 | A |
5971933 | Gopakumaran et al. | Oct 1999 | A |
5983126 | Wittkampf | Nov 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6024702 | Iversen | Feb 2000 | A |
6096728 | Collins et al. | Aug 2000 | A |
6120476 | Fung et al. | Sep 2000 | A |
6123699 | Webster, Jr. | Sep 2000 | A |
6126649 | Vantassel et al. | Oct 2000 | A |
6136021 | Tockman et al. | Oct 2000 | A |
6157862 | Brownlee et al. | Dec 2000 | A |
6161029 | Spreigl et al. | Dec 2000 | A |
6166048 | Bencherif | Dec 2000 | A |
6171277 | Ponzi | Jan 2001 | B1 |
6183463 | Webster, Jr. | Feb 2001 | B1 |
6198970 | Freed et al. | Mar 2001 | B1 |
6198974 | Webster, Jr. | Mar 2001 | B1 |
6201994 | Warman et al. | Mar 2001 | B1 |
6208881 | Champeau | Mar 2001 | B1 |
6210339 | Kiepen et al. | Apr 2001 | B1 |
6212435 | Lattner et al. | Apr 2001 | B1 |
6216045 | Black et al. | Apr 2001 | B1 |
6236892 | Feler | May 2001 | B1 |
6240320 | Spehr et al. | May 2001 | B1 |
6251126 | Ottenhoff et al. | Jun 2001 | B1 |
6269269 | Ottenhoff et al. | Jul 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6295475 | Morgan | Sep 2001 | B1 |
6360740 | Ward et al. | Mar 2002 | B1 |
6397108 | Camps et al. | May 2002 | B1 |
6400976 | Champeau | Jun 2002 | B1 |
6415183 | Scheiner et al. | Jul 2002 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6438427 | Rexhausen et al. | Aug 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6463327 | Lurie et al. | Oct 2002 | B1 |
6493590 | Wessman et al. | Dec 2002 | B1 |
6508802 | Rosengart et al. | Jan 2003 | B1 |
6526321 | Spehr | Feb 2003 | B1 |
6569114 | Ponzi et al. | May 2003 | B2 |
6584362 | Scheiner et al. | Jun 2003 | B1 |
6585718 | Hayzelden et al. | Jul 2003 | B2 |
6587726 | Lurie et al. | Jul 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6610713 | Tracey | Aug 2003 | B2 |
6630611 | Malowaniec | Oct 2003 | B1 |
6643552 | Edell et al. | Nov 2003 | B2 |
6651652 | Waard | Nov 2003 | B1 |
6682526 | Jones et al. | Jan 2004 | B1 |
6702780 | Gilboa et al. | Mar 2004 | B1 |
6718208 | Hill et al. | Apr 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6757970 | Kuzma et al. | Jul 2004 | B1 |
6778854 | Puskas | Aug 2004 | B2 |
6779257 | Kiepen et al. | Aug 2004 | B2 |
6844713 | Steber et al. | Jan 2005 | B2 |
RE38705 | Hill et al. | Feb 2005 | E |
6881211 | Schweikert et al. | Apr 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6907285 | Denker et al. | Jun 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6981314 | Black et al. | Jan 2006 | B2 |
6999820 | Jordan | Feb 2006 | B2 |
7018374 | Schon et al. | Mar 2006 | B2 |
7047627 | Black et al. | May 2006 | B2 |
7071194 | Teng | Jul 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7077823 | McDaniel | Jul 2006 | B2 |
7082331 | Park et al. | Jul 2006 | B1 |
7130700 | Gardeski et al. | Oct 2006 | B2 |
7142903 | Rodriguez et al. | Nov 2006 | B2 |
7149585 | Wessman et al. | Dec 2006 | B2 |
7155278 | King et al. | Dec 2006 | B2 |
7168429 | Matthews et al. | Jan 2007 | B2 |
7184829 | Hill et al. | Feb 2007 | B2 |
7206636 | Turcott | Apr 2007 | B1 |
7212867 | Van et al. | May 2007 | B2 |
7225016 | Koh | May 2007 | B1 |
7225019 | Jahns et al. | May 2007 | B2 |
7229429 | Martin et al. | Jun 2007 | B2 |
7231260 | Wallace et al. | Jun 2007 | B2 |
7235070 | Vanney | Jun 2007 | B2 |
7269459 | Koh | Sep 2007 | B1 |
7277757 | Casavant et al. | Oct 2007 | B2 |
7283875 | Larsson et al. | Oct 2007 | B2 |
7340302 | Falkenberg et al. | Mar 2008 | B1 |
7363085 | Benser et al. | Apr 2008 | B1 |
7363086 | Koh et al. | Apr 2008 | B1 |
7371220 | Koh et al. | May 2008 | B1 |
7416552 | Paul et al. | Aug 2008 | B2 |
7421296 | Benser et al. | Sep 2008 | B1 |
7454244 | Kassab et al. | Nov 2008 | B2 |
7519425 | Benser et al. | Apr 2009 | B2 |
7519426 | Koh et al. | Apr 2009 | B1 |
7522953 | Gharib et al. | Apr 2009 | B2 |
7553305 | Honebrink et al. | Jun 2009 | B2 |
7555349 | Wessman et al. | Jun 2009 | B2 |
7569029 | Clark et al. | Aug 2009 | B2 |
7591265 | Lee et al. | Sep 2009 | B2 |
7593760 | Rodriguez et al. | Sep 2009 | B2 |
7613524 | Jordan | Nov 2009 | B2 |
7636600 | Koh | Dec 2009 | B1 |
7670284 | Padget et al. | Mar 2010 | B2 |
7672728 | Libbus et al. | Mar 2010 | B2 |
7672729 | Koh et al. | Mar 2010 | B2 |
7676275 | Farazi et al. | Mar 2010 | B1 |
7676910 | Kiepen et al. | Mar 2010 | B2 |
7697984 | Hill et al. | Apr 2010 | B2 |
7747323 | Libbus et al. | Jun 2010 | B2 |
7771388 | Olsen et al. | Aug 2010 | B2 |
7783362 | Whitehurst et al. | Aug 2010 | B2 |
7794407 | Rothenberg | Sep 2010 | B2 |
7797050 | Libbus et al. | Sep 2010 | B2 |
7813805 | Farazi | Oct 2010 | B1 |
7819883 | Westlund et al. | Oct 2010 | B2 |
7840270 | Ignagni et al. | Nov 2010 | B2 |
7853302 | Rodriguez et al. | Dec 2010 | B2 |
7869865 | Govari et al. | Jan 2011 | B2 |
7891085 | Kuzma et al. | Feb 2011 | B1 |
7925352 | Stack et al. | Apr 2011 | B2 |
7949409 | Bly et al. | May 2011 | B2 |
7949412 | Harrison et al. | May 2011 | B1 |
7962215 | Ignagni | Jun 2011 | B2 |
7970475 | Tehrani et al. | Jun 2011 | B2 |
7972323 | Bencini et al. | Jul 2011 | B1 |
7974693 | David et al. | Jul 2011 | B2 |
7974705 | Zdeblick et al. | Jul 2011 | B2 |
7979128 | Tehrani et al. | Jul 2011 | B2 |
7994655 | Bauer et al. | Aug 2011 | B2 |
8000765 | Rodriguez et al. | Aug 2011 | B2 |
8019439 | Kuzma et al. | Sep 2011 | B2 |
8021327 | Selkee | Sep 2011 | B2 |
8036750 | Caparso et al. | Oct 2011 | B2 |
8050765 | Lee et al. | Nov 2011 | B2 |
8052607 | Byrd | Nov 2011 | B2 |
8104470 | Lee et al. | Jan 2012 | B2 |
8116872 | Tehrani et al. | Feb 2012 | B2 |
8121692 | Haefner et al. | Feb 2012 | B2 |
8135471 | Zhang et al. | Mar 2012 | B2 |
8140164 | Tehrani et al. | Mar 2012 | B2 |
8147486 | Honour et al. | Apr 2012 | B2 |
8160701 | Zhao et al. | Apr 2012 | B2 |
8160711 | Tehrani et al. | Apr 2012 | B2 |
8195297 | Penner | Jun 2012 | B2 |
8200336 | Tehrani et al. | Jun 2012 | B2 |
8206343 | Racz | Jun 2012 | B2 |
8224456 | Daglow et al. | Jul 2012 | B2 |
8233987 | Gelfand et al. | Jul 2012 | B2 |
8233993 | Jordan | Jul 2012 | B2 |
8239037 | Glenn et al. | Aug 2012 | B2 |
8244358 | Tehrani et al. | Aug 2012 | B2 |
8244359 | Gelfand et al. | Aug 2012 | B2 |
8244378 | Bly et al. | Aug 2012 | B2 |
8255056 | Tehrani | Aug 2012 | B2 |
8256419 | Sinderby et al. | Sep 2012 | B2 |
8265736 | Sathaye et al. | Sep 2012 | B2 |
8265759 | Tehrani et al. | Sep 2012 | B2 |
8275440 | Rodriguez et al. | Sep 2012 | B2 |
8280513 | Tehrani et al. | Oct 2012 | B2 |
8315713 | Burnes et al. | Nov 2012 | B2 |
8321808 | Goetz et al. | Nov 2012 | B2 |
8335567 | Tehrani et al. | Dec 2012 | B2 |
8340783 | Sommer et al. | Dec 2012 | B2 |
8348941 | Tehrani | Jan 2013 | B2 |
8369954 | Stack et al. | Feb 2013 | B2 |
8374704 | Desai et al. | Feb 2013 | B2 |
8388541 | Messerly et al. | Mar 2013 | B2 |
8388546 | Rothenberg | Mar 2013 | B2 |
8391956 | Zellers et al. | Mar 2013 | B2 |
8401640 | Zhao et al. | Mar 2013 | B2 |
8401651 | Caparso et al. | Mar 2013 | B2 |
8406883 | Barker | Mar 2013 | B1 |
8406885 | Ignagni et al. | Mar 2013 | B2 |
8412331 | Tehrani et al. | Apr 2013 | B2 |
8412350 | Bly | Apr 2013 | B2 |
8428711 | Lin et al. | Apr 2013 | B2 |
8428726 | Ignagni et al. | Apr 2013 | B2 |
8428730 | Stack et al. | Apr 2013 | B2 |
8433412 | Westlund et al. | Apr 2013 | B1 |
8442638 | Libbus et al. | May 2013 | B2 |
8457764 | Ramachandran et al. | Jun 2013 | B2 |
8467876 | Tehrani | Jun 2013 | B2 |
8473068 | Farazi | Jun 2013 | B2 |
8478412 | Ignagni et al. | Jul 2013 | B2 |
8478413 | Karamanoglu et al. | Jul 2013 | B2 |
8478426 | Barker | Jul 2013 | B2 |
8483834 | Lee et al. | Jul 2013 | B2 |
8504158 | Karamanoglu et al. | Aug 2013 | B2 |
8504161 | Kornet et al. | Aug 2013 | B1 |
8509901 | Tehrani | Aug 2013 | B2 |
8509902 | Cho et al. | Aug 2013 | B2 |
8509919 | Yoo et al. | Aug 2013 | B2 |
8512256 | Rothenberg | Aug 2013 | B2 |
8522779 | Lee et al. | Sep 2013 | B2 |
8527036 | Jalde et al. | Sep 2013 | B2 |
8532793 | Morris et al. | Sep 2013 | B2 |
8554323 | Haefner et al. | Oct 2013 | B2 |
8560072 | Caparso et al. | Oct 2013 | B2 |
8560086 | Just et al. | Oct 2013 | B2 |
8571662 | Hoffer | Oct 2013 | B2 |
8571685 | Daglow et al. | Oct 2013 | B2 |
8615297 | Sathaye et al. | Dec 2013 | B2 |
8617228 | Wittenberger et al. | Dec 2013 | B2 |
8620412 | Griffiths et al. | Dec 2013 | B2 |
8620450 | Tockman et al. | Dec 2013 | B2 |
8626292 | McCabe et al. | Jan 2014 | B2 |
8630707 | Zhao et al. | Jan 2014 | B2 |
8644939 | Wilson et al. | Feb 2014 | B2 |
8644952 | Desai et al. | Feb 2014 | B2 |
8646172 | Kuzma et al. | Feb 2014 | B2 |
8650747 | Kuzma et al. | Feb 2014 | B2 |
8676323 | Ignagni et al. | Mar 2014 | B2 |
8676344 | Desai et al. | Mar 2014 | B2 |
8694123 | Wahlstrand et al. | Apr 2014 | B2 |
8696656 | Abboud et al. | Apr 2014 | B2 |
8706223 | Zhou et al. | Apr 2014 | B2 |
8706235 | Karamanoglu et al. | Apr 2014 | B2 |
8706236 | Ignagni et al. | Apr 2014 | B2 |
8718763 | Zhou et al. | May 2014 | B2 |
8725259 | Kornet et al. | May 2014 | B2 |
8738154 | Zdeblick et al. | May 2014 | B2 |
8755889 | Scheiner | Jun 2014 | B2 |
8774907 | Rothenberg | Jul 2014 | B2 |
8781578 | McCabe et al. | Jul 2014 | B2 |
8781582 | Ziegler et al. | Jul 2014 | B2 |
8781583 | Cornelussen et al. | Jul 2014 | B2 |
8801693 | He et al. | Aug 2014 | B2 |
8805511 | Karamanoglu et al. | Aug 2014 | B2 |
8838245 | Lin et al. | Sep 2014 | B2 |
8858455 | Rothenberg | Oct 2014 | B2 |
8863742 | Blomquist et al. | Oct 2014 | B2 |
8886277 | Kim et al. | Nov 2014 | B2 |
8897879 | Karamanoglu et al. | Nov 2014 | B2 |
8903507 | Desai et al. | Dec 2014 | B2 |
8903509 | Tockman et al. | Dec 2014 | B2 |
8909341 | Gelfand et al. | Dec 2014 | B2 |
8914113 | Zhang et al. | Dec 2014 | B2 |
8918169 | Kassab et al. | Dec 2014 | B2 |
8918987 | Kuzma et al. | Dec 2014 | B2 |
8923971 | Haefner et al. | Dec 2014 | B2 |
8942823 | Desai et al. | Jan 2015 | B2 |
8942824 | Yoo et al. | Jan 2015 | B2 |
8948884 | Ramachandran et al. | Feb 2015 | B2 |
8968299 | Kauphusman et al. | Mar 2015 | B2 |
8972015 | Stack et al. | Mar 2015 | B2 |
8983602 | Sathaye et al. | Mar 2015 | B2 |
9008775 | Sathaye et al. | Apr 2015 | B2 |
9026231 | Hoffer | May 2015 | B2 |
9037264 | Just et al. | May 2015 | B2 |
9042981 | Yoo et al. | May 2015 | B2 |
9072864 | Putz | Jul 2015 | B2 |
9072899 | Nickloes | Jul 2015 | B1 |
9108058 | Hoffer | Aug 2015 | B2 |
9108059 | Hoffer | Aug 2015 | B2 |
9125578 | Grunwald | Sep 2015 | B2 |
9138580 | Ignagni et al. | Sep 2015 | B2 |
9138585 | Saha et al. | Sep 2015 | B2 |
9149642 | McCabe et al. | Oct 2015 | B2 |
9168377 | Hoffer | Oct 2015 | B2 |
9205258 | Simon et al. | Dec 2015 | B2 |
9216291 | Lee et al. | Dec 2015 | B2 |
9220898 | Hoffer | Dec 2015 | B2 |
9226688 | Jacobsen et al. | Jan 2016 | B2 |
9226689 | Jacobsen et al. | Jan 2016 | B2 |
9242088 | Thakkar et al. | Jan 2016 | B2 |
9259573 | Tehrani et al. | Feb 2016 | B2 |
9295846 | Westlund et al. | Mar 2016 | B2 |
9314618 | Imran et al. | Apr 2016 | B2 |
9333363 | Hoffer et al. | May 2016 | B2 |
9345422 | Rothenberg | May 2016 | B2 |
9370657 | Tehrani et al. | Jun 2016 | B2 |
9398931 | Wittenberger et al. | Jul 2016 | B2 |
9415188 | He et al. | Aug 2016 | B2 |
9427566 | Reed et al. | Aug 2016 | B2 |
9427588 | Sathaye et al. | Aug 2016 | B2 |
9474894 | Mercanzini et al. | Oct 2016 | B2 |
9485873 | Shah et al. | Nov 2016 | B2 |
9498625 | Bauer et al. | Nov 2016 | B2 |
9498631 | Demmer et al. | Nov 2016 | B2 |
9504837 | Demmer et al. | Nov 2016 | B2 |
9532724 | Grunwald et al. | Jan 2017 | B2 |
9533160 | Brooke et al. | Jan 2017 | B2 |
9539429 | Brooke et al. | Jan 2017 | B2 |
9545511 | Thakkar et al. | Jan 2017 | B2 |
9561369 | Burnes et al. | Feb 2017 | B2 |
9566436 | Hoffer et al. | Feb 2017 | B2 |
9572982 | Burnes et al. | Feb 2017 | B2 |
9597509 | Hoffer et al. | Mar 2017 | B2 |
9615759 | Hurezan et al. | Apr 2017 | B2 |
9623252 | Sathaye et al. | Apr 2017 | B2 |
9662494 | Young et al. | May 2017 | B2 |
9682235 | O'Mahony et al. | Jun 2017 | B1 |
9694185 | Bauer | Jul 2017 | B2 |
9717899 | Kuzma et al. | Aug 2017 | B2 |
9724018 | Cho et al. | Aug 2017 | B2 |
9744351 | Gelfand et al. | Aug 2017 | B1 |
9776005 | Meyyappan et al. | Oct 2017 | B2 |
9861817 | Cho et al. | Jan 2018 | B2 |
9872989 | Jung et al. | Jan 2018 | B2 |
9884178 | Bouton et al. | Feb 2018 | B2 |
9884179 | Bouton et al. | Feb 2018 | B2 |
9919149 | Imran et al. | Mar 2018 | B2 |
9931504 | Thakkar et al. | Apr 2018 | B2 |
9950167 | Hoffer et al. | Apr 2018 | B2 |
9956396 | Young et al. | May 2018 | B2 |
9968785 | Hoffer et al. | May 2018 | B2 |
9968786 | Bauer et al. | May 2018 | B2 |
20010052345 | Niazi | Dec 2001 | A1 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020056454 | Samzelius | May 2002 | A1 |
20020065544 | Smits et al. | May 2002 | A1 |
20020087156 | Maguire et al. | Jul 2002 | A1 |
20020128546 | Silver | Sep 2002 | A1 |
20020188325 | Hill et al. | Dec 2002 | A1 |
20030078623 | Weinberg et al. | Apr 2003 | A1 |
20030195571 | Burnes et al. | Oct 2003 | A1 |
20040003813 | Banner et al. | Jan 2004 | A1 |
20040010303 | Bolea et al. | Jan 2004 | A1 |
20040030362 | Hill et al. | Feb 2004 | A1 |
20040044377 | Larsson et al. | Mar 2004 | A1 |
20040064069 | Reynolds et al. | Apr 2004 | A1 |
20040077936 | Larsson et al. | Apr 2004 | A1 |
20040088015 | Casavant et al. | May 2004 | A1 |
20040111139 | McCreery | Jun 2004 | A1 |
20040186543 | King et al. | Sep 2004 | A1 |
20040210261 | King et al. | Oct 2004 | A1 |
20050004565 | Vanney | Jan 2005 | A1 |
20050013879 | Lin et al. | Jan 2005 | A1 |
20050021102 | Ignagni et al. | Jan 2005 | A1 |
20050027338 | Hill | Feb 2005 | A1 |
20050033136 | Govari et al. | Feb 2005 | A1 |
20050033137 | Oral et al. | Feb 2005 | A1 |
20050043765 | Williams et al. | Feb 2005 | A1 |
20050065567 | Lee et al. | Mar 2005 | A1 |
20050070981 | Verma | Mar 2005 | A1 |
20050075578 | Gharib et al. | Apr 2005 | A1 |
20050085865 | Tehrani | Apr 2005 | A1 |
20050085866 | Tehrani | Apr 2005 | A1 |
20050085867 | Tehrani et al. | Apr 2005 | A1 |
20050085868 | Tehrani et al. | Apr 2005 | A1 |
20050085869 | Tehrani et al. | Apr 2005 | A1 |
20050096710 | Kieval | May 2005 | A1 |
20050109340 | Tehrani | May 2005 | A1 |
20050113710 | Stahmann et al. | May 2005 | A1 |
20050115561 | Stahmann et al. | Jun 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050138791 | Black et al. | Jun 2005 | A1 |
20050138792 | Black et al. | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050165457 | Benser et al. | Jul 2005 | A1 |
20050182454 | Gharib et al. | Aug 2005 | A1 |
20050187584 | Denker et al. | Aug 2005 | A1 |
20050192655 | Black et al. | Sep 2005 | A1 |
20050251238 | Wallace et al. | Nov 2005 | A1 |
20050251239 | Wallace et al. | Nov 2005 | A1 |
20050288728 | Libbus et al. | Dec 2005 | A1 |
20050288730 | Deem et al. | Dec 2005 | A1 |
20060030894 | Tehrani | Feb 2006 | A1 |
20060035849 | Spiegelman et al. | Feb 2006 | A1 |
20060058852 | Koh et al. | Mar 2006 | A1 |
20060074449 | Denker et al. | Apr 2006 | A1 |
20060122661 | Mandell | Jun 2006 | A1 |
20060122662 | Tehrani et al. | Jun 2006 | A1 |
20060130833 | Younes | Jun 2006 | A1 |
20060142815 | Tehrani et al. | Jun 2006 | A1 |
20060149334 | Tehrani et al. | Jul 2006 | A1 |
20060155222 | Sherman et al. | Jul 2006 | A1 |
20060167523 | Tehrani et al. | Jul 2006 | A1 |
20060188325 | Dolan | Aug 2006 | A1 |
20060195159 | Bradley et al. | Aug 2006 | A1 |
20060217791 | Spinka et al. | Sep 2006 | A1 |
20060224209 | Meyer | Oct 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060229687 | Goetz | Oct 2006 | A1 |
20060247729 | Tehrani et al. | Nov 2006 | A1 |
20060253161 | Libbus et al. | Nov 2006 | A1 |
20060253182 | King | Nov 2006 | A1 |
20060258667 | Teng | Nov 2006 | A1 |
20060259107 | Caparso et al. | Nov 2006 | A1 |
20060282131 | Caparso et al. | Dec 2006 | A1 |
20060287679 | Stone | Dec 2006 | A1 |
20070005053 | Dando | Jan 2007 | A1 |
20070021795 | Tehrani | Jan 2007 | A1 |
20070027448 | Paul et al. | Feb 2007 | A1 |
20070087314 | Gomo | Apr 2007 | A1 |
20070093875 | Chavan et al. | Apr 2007 | A1 |
20070106357 | Denker et al. | May 2007 | A1 |
20070112402 | Grill et al. | May 2007 | A1 |
20070112403 | Moffitt et al. | May 2007 | A1 |
20070118183 | Gelfand et al. | May 2007 | A1 |
20070150006 | Libbus et al. | Jun 2007 | A1 |
20070168007 | Kuzma et al. | Jul 2007 | A1 |
20070173900 | Siegel et al. | Jul 2007 | A1 |
20070191908 | Jacob et al. | Aug 2007 | A1 |
20070196780 | Ware et al. | Aug 2007 | A1 |
20070203549 | Demarais et al. | Aug 2007 | A1 |
20070208388 | Jahns et al. | Sep 2007 | A1 |
20070221224 | Pittman et al. | Sep 2007 | A1 |
20070240718 | Daly | Oct 2007 | A1 |
20070250056 | Vanney | Oct 2007 | A1 |
20070250162 | Royalty | Oct 2007 | A1 |
20070255379 | Williams et al. | Nov 2007 | A1 |
20070265611 | Ignagni et al. | Nov 2007 | A1 |
20070288076 | Bulkes et al. | Dec 2007 | A1 |
20080039916 | Colliou et al. | Feb 2008 | A1 |
20080065002 | Lobl et al. | Mar 2008 | A1 |
20080121231 | Sinderby | May 2008 | A1 |
20080125828 | Ignagni et al. | May 2008 | A1 |
20080161878 | Tehrani et al. | Jul 2008 | A1 |
20080167695 | Tehrani et al. | Jul 2008 | A1 |
20080177347 | Tehrani et al. | Jul 2008 | A1 |
20080183186 | Bly et al. | Jul 2008 | A1 |
20080183187 | Bly | Jul 2008 | A1 |
20080183239 | Tehrani et al. | Jul 2008 | A1 |
20080183240 | Tehrani et al. | Jul 2008 | A1 |
20080183253 | Bly | Jul 2008 | A1 |
20080183254 | Bly et al. | Jul 2008 | A1 |
20080183255 | Bly et al. | Jul 2008 | A1 |
20080183259 | Bly et al. | Jul 2008 | A1 |
20080183264 | Bly et al. | Jul 2008 | A1 |
20080183265 | Bly et al. | Jul 2008 | A1 |
20080188903 | Tehrani et al. | Aug 2008 | A1 |
20080215106 | Lee et al. | Sep 2008 | A1 |
20080288010 | Tehrani et al. | Nov 2008 | A1 |
20080288015 | Tehrani et al. | Nov 2008 | A1 |
20080312712 | Penner | Dec 2008 | A1 |
20080312725 | Penner | Dec 2008 | A1 |
20090024047 | Shipley et al. | Jan 2009 | A1 |
20090036947 | Westlund et al. | Feb 2009 | A1 |
20090118785 | Ignagni et al. | May 2009 | A1 |
20090275956 | Burnes et al. | Nov 2009 | A1 |
20090275996 | Burnes et al. | Nov 2009 | A1 |
20090276022 | Burnes et al. | Nov 2009 | A1 |
20100022950 | Anderson et al. | Jan 2010 | A1 |
20100036451 | Hoffer | Feb 2010 | A1 |
20100077606 | Black et al. | Apr 2010 | A1 |
20100094376 | Penner | Apr 2010 | A1 |
20100114227 | Cholette | May 2010 | A1 |
20100114254 | Kornet | May 2010 | A1 |
20100198296 | Ignagni et al. | Aug 2010 | A1 |
20100204766 | Zdeblick et al. | Aug 2010 | A1 |
20100268311 | Cardinal et al. | Oct 2010 | A1 |
20100319691 | Lurie et al. | Dec 2010 | A1 |
20110060381 | Ignagni et al. | Mar 2011 | A1 |
20110077726 | Westlund et al. | Mar 2011 | A1 |
20110118815 | Kuzma et al. | May 2011 | A1 |
20110230932 | Tehrani et al. | Sep 2011 | A1 |
20110230935 | Zdeblick | Sep 2011 | A1 |
20110230945 | Ohtaka et al. | Sep 2011 | A1 |
20110270358 | Davis et al. | Nov 2011 | A1 |
20110288609 | Tehrani | Nov 2011 | A1 |
20120035684 | Thompson et al. | Feb 2012 | A1 |
20120053654 | Tehrani et al. | Mar 2012 | A1 |
20120078320 | Schotzko et al. | Mar 2012 | A1 |
20120130217 | Kauphusman et al. | May 2012 | A1 |
20120158091 | Tehrani et al. | Jun 2012 | A1 |
20120209284 | Westlund et al. | Aug 2012 | A1 |
20120215278 | Penner | Aug 2012 | A1 |
20120323293 | Tehrani et al. | Dec 2012 | A1 |
20130018247 | Glenn et al. | Jan 2013 | A1 |
20130018427 | Pham et al. | Jan 2013 | A1 |
20130023972 | Kuzma et al. | Jan 2013 | A1 |
20130030496 | Karamanoglu et al. | Jan 2013 | A1 |
20130030497 | Karamanoglu et al. | Jan 2013 | A1 |
20130030498 | Karamanoglu et al. | Jan 2013 | A1 |
20130060245 | Grunewald et al. | Mar 2013 | A1 |
20130116743 | Karamanoglu et al. | May 2013 | A1 |
20130123891 | Swanson | May 2013 | A1 |
20130131743 | Yamasaki et al. | May 2013 | A1 |
20130158625 | Gelfand et al. | Jun 2013 | A1 |
20130165989 | Gelfand et al. | Jun 2013 | A1 |
20130167372 | Black et al. | Jul 2013 | A1 |
20130197601 | Tehrani et al. | Aug 2013 | A1 |
20130237906 | Park et al. | Sep 2013 | A1 |
20130268018 | Brooke et al. | Oct 2013 | A1 |
20130289686 | Masson et al. | Oct 2013 | A1 |
20130296964 | Tehrani | Nov 2013 | A1 |
20130296973 | Tehrani et al. | Nov 2013 | A1 |
20130317587 | Barker | Nov 2013 | A1 |
20130333696 | Lee et al. | Dec 2013 | A1 |
20140067032 | Morris et al. | Mar 2014 | A1 |
20140088580 | Wittenberger et al. | Mar 2014 | A1 |
20140114371 | Westlund et al. | Apr 2014 | A1 |
20140121716 | Casavant et al. | May 2014 | A1 |
20140128953 | Zhao et al. | May 2014 | A1 |
20140148780 | Putz | May 2014 | A1 |
20140316486 | Zhou et al. | Oct 2014 | A1 |
20140324115 | Ziegler et al. | Oct 2014 | A1 |
20140378803 | Geistert et al. | Dec 2014 | A1 |
20150018839 | Morris et al. | Jan 2015 | A1 |
20150034081 | Tehrani et al. | Feb 2015 | A1 |
20150045810 | Hoffer et al. | Feb 2015 | A1 |
20150045848 | Cho et al. | Feb 2015 | A1 |
20150119950 | Demmer et al. | Apr 2015 | A1 |
20150165207 | Karamanoglu | Jun 2015 | A1 |
20150196354 | Haverkost et al. | Jul 2015 | A1 |
20150196356 | Kauphusman et al. | Jul 2015 | A1 |
20150231348 | Lee et al. | Aug 2015 | A1 |
20150250982 | Osypka et al. | Sep 2015 | A1 |
20150265833 | Meyyappan et al. | Sep 2015 | A1 |
20150283340 | Zhang et al. | Oct 2015 | A1 |
20150290476 | Krocak et al. | Oct 2015 | A1 |
20150359487 | Coulombe | Dec 2015 | A1 |
20150374252 | De et al. | Dec 2015 | A1 |
20150374991 | Morris et al. | Dec 2015 | A1 |
20160001072 | Gelfand et al. | Jan 2016 | A1 |
20160144078 | Young et al. | May 2016 | A1 |
20160193460 | Xu et al. | Jul 2016 | A1 |
20160228696 | Imran et al. | Aug 2016 | A1 |
20160239627 | Cerny et al. | Aug 2016 | A1 |
20160256692 | Baru | Sep 2016 | A1 |
20160310730 | Martins et al. | Oct 2016 | A1 |
20160331326 | Xiang et al. | Nov 2016 | A1 |
20160367815 | Hoffer | Dec 2016 | A1 |
20170007825 | Thakkar et al. | Jan 2017 | A1 |
20170013713 | Shah et al. | Jan 2017 | A1 |
20170021166 | Bauer et al. | Jan 2017 | A1 |
20170028191 | Mercanzini et al. | Feb 2017 | A1 |
20170036017 | Tehrani et al. | Feb 2017 | A1 |
20170050033 | Wechter | Feb 2017 | A1 |
20170143973 | Tehrani | May 2017 | A1 |
20170143975 | Hoffer et al. | May 2017 | A1 |
20170196503 | Narayan et al. | Jul 2017 | A1 |
20170224993 | Sathaye et al. | Aug 2017 | A1 |
20170232250 | Kim et al. | Aug 2017 | A1 |
20170252558 | O'Mahony et al. | Sep 2017 | A1 |
20170291023 | Kuzma et al. | Oct 2017 | A1 |
20170296812 | O'Mahony et al. | Oct 2017 | A1 |
20170312006 | McFarlin et al. | Nov 2017 | A1 |
20170312507 | Bauer et al. | Nov 2017 | A1 |
20170312508 | Bauer et al. | Nov 2017 | A1 |
20170312509 | Bauer et al. | Nov 2017 | A1 |
20170326359 | Gelfand et al. | Nov 2017 | A1 |
20170347921 | Haber et al. | Dec 2017 | A1 |
20180001086 | Bartholomew et al. | Jan 2018 | A1 |
20180008821 | Gonzalez et al. | Jan 2018 | A1 |
20180110562 | Govari et al. | Apr 2018 | A1 |
20180117334 | Jung | May 2018 | A1 |
Number | Date | Country |
---|---|---|
1652839 | Aug 2005 | CN |
102143781 | Aug 2011 | CN |
0993840 | Apr 2000 | EP |
1304135 | Apr 2003 | EP |
0605796 | Aug 2003 | EP |
2489395 | Aug 2012 | EP |
2801509 | Jun 2001 | FR |
H08510677 | Nov 1996 | JP |
2003503119 | Jan 2003 | JP |
2010516353 | May 2010 | JP |
2011200571 | Oct 2011 | JP |
2012000195 | Jan 2012 | JP |
WO-9407564 | Apr 1994 | WO |
WO-9508357 | Mar 1995 | WO |
WO-9964105 | Dec 1999 | WO |
WO-9965561 | Dec 1999 | WO |
WO-0100273 | Jan 2001 | WO |
WO-02058785 | Aug 2002 | WO |
WO-03094855 | Nov 2003 | WO |
WO-2006110338 | Oct 2006 | WO |
WO-2006115877 | Nov 2006 | WO |
WO-2007053508 | May 2007 | WO |
WO-2008092246 | Aug 2008 | WO |
WO-2008094344 | Aug 2008 | WO |
WO-2009006337 | Jan 2009 | WO |
WO-2009134459 | Nov 2009 | WO |
WO-2010029842 | Mar 2010 | WO |
WO-2010148412 | Dec 2010 | WO |
WO-2011158410 | Dec 2011 | WO |
WO-2012106533 | Aug 2012 | WO |
WO-2013131187 | Sep 2013 | WO |
WO-2013188965 | Dec 2013 | WO |
Entry |
---|
Antonica A., et al., “Vagal Control of Lymphocyte Release from Rat Thymus,” Journal of the Autonomic Nervous System, Elsevier, vol. 48(3), Aug. 1994, pp. 187-197. |
Ayas N.T., et al., “Prevention of Human Diaphragm Atrophy with Short periods of Electrical Stimulation,” American Journal of Respiratory and Critical Care Medicine, Jun. 1999, vol. 159(6), pp. 2018-2020. |
Borovikovaa L.V., et al., “Role of Vagus Nerve Signaling in CNI-1493-Mediated Suppression of Acute Inflammation,” Autonomic Neuroscience: Basic and Clinical, vol. 85 (1-3), Dec. 20, 2000, pp. 141-147. |
Borovikovaa L.V., et al., “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin,” Nature, Macmillan Magazines Ltd, vol. 405, May 25, 2000, pp. 458-462. |
Chinese Search Report for Application No. CN2013/80023357.5, dated Jul. 24, 2015. |
Co-pending U.S. Appl. No. 15/606,867, filed May 26, 2017. |
Daggeti, W.M. et al., “Intracaval Electrophrenic Stimulation. I. Experimental Application during Barbiturate Intoxication Hemorrhage and Gang,” Journal of Thoracic and Cardiovascular Surgery, 1966, vol. 51 (5), pp. 676-884. |
Daggeti, W.M. et al., “Intracaval electrophrenic stimulation. II. Studies on Pulmonary Mechanics Surface Tension Urine Flow and Bilateral Ph,” Journal of Thoracic and Cardiovascular Surgery, 1970, vol. 60(1 ), pp. 98-107. |
De Gregorio, M.A. et al., “The Gunther Tulip Retrievable Filter: Prolonged Temporary Filtration by Repositioning within the Inferior Vena Cava,” Journal of Vascular and Interventional Radiology, 2003, vol. 14, pp. 1259-1265. |
Deng Y-J et al., “The Effect of Positive Pressure Ventilation Combined with Diaphragm Pacing on Respiratory Mechanics in Patients with Respiratory Failure; Respiratory Mechanics,” Chinese critical care medicine, Apr. 2011, vol. 23(4), pp. 213-215. |
European Search Report for Application No. 13758363, dated Nov. 12, 2015. |
European Search Report for Application No. EP17169051.4, dated Sep. 8, 2017, 7 pages. |
Extended European Search Report for Application No. 14864542.7, dated Jun. 2, 2017, 8 pages. |
Extended European Search Report for Application No. 15740415.3, dated Jul. 7, 2017. |
Fleshner M., et al., “Thermogenic and Corticosterone Responses to Intravenous Cytokines (IL-1β and TNF-α) are Attenuated by Subdiaphragmatic Vagotomy,” Journal of Neuroimmunology, vol. 86, Jun. 1998, pp. 134-141. |
Frisch S., “A Feasibility Study of a Novel Minimally Invasive Approach for Diaphragm Pacing,” Master of Science Thesis, Simon Fraser University, 2009, p. 148. |
Furman, S., “Transvenous Stimulation of the Phrenic Nerves,” Journal of Thoracic and Cardiovascular Surgery, 1971, vol. 62 (5), pp. 743-751. |
Gaykema R.P.A. et al., “Subdiaphragmatic Vagotomy Suppresses Endotoxin-Induced Activation of Hypothalamic Corticotropin-Releasing Hormone Neurons and ACTH Secretion,” Endocrinology, The Endocrine Society, vol. 136 (10), 1995, pp. 4717-4720. |
Gupta A.K., “Respiration Rate Measurement Based on Impedance Pneumography,” Data Acquisition Products, Texas Instruments, Application Report, SBAA181, Feb. 2011, 11 pages. |
Guslandi M., “Nicotine Treatment for Ulcerative Colitis,” The British Journal of Clinical Pharmacology, Blackwell Science Ltd, vol. 48, 1999, pp. 481-484. |
Hoffer J.A. et al., “Diaphragm Pacing with Endovascular Electrodes”, IFESS 2010—International Functional Electrical Stimulation Society, 15th Anniversary Conference, Vienna, Austria, Sep. 2010. |
Japanese Office Action in corresponding Japanese Application No. 2014-560202, dated Dec. 6, 2016, 4 pages. |
Japanese Office Action in corresponding Japanese Application No. 2014-560202, dated Oct. 17, 2017, 5 pages. |
Kawashima K., et al., “Extraneuronal Cholinergic System in Lymphocytes,” Pharmacology & Therapeutics, Elsevier, vol. 86, 2000, pp. 29-48. |
Levine S., et al., “Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans,” New England Journal of Medicine, 2008, vol. 358, pp. 1327-1335. |
Lung pacer: Therapy, News.< http://lungpacer.com>. Accessed Dec. 27, 2016. |
Madretsma, G.S., et al., “Nicotine Inhibits the In-vitro Production of Interleukin 2 and Tumour Necrosis Factor-α by Human Mononuclear Cells,” Immunopharmacology, Elsevier, vol. 35 (1), Oct. 1996, pp. 47-51. |
Marcy, T.W. et al., “Diaphragm Pacing for Ventilatory Insufficiency,” Journal of Intensive Care Medicine, 1987, vol. 2 (6), pp. 345-353. |
Meyyappan R., “Diaphragm Pacing during Controlled Mechanical Ventilation: Pre-Clinical Observations Reveal a Substantial Improvement in Respiratory Mechanics”, 17th Biennial Canadian Biomechanics Society Meeting, Burnaby, BC, Jun. 6-9, 2012. |
Nabutovsky, Y., et al., “Lead Design and Initial Applications of a New Lead for Long-Term Endovascular Vagal Stimulation,” PACE, Blackwell Publishing, Inc, vol. 30(1), Jan. 2007, pp. S215-S218. |
Notification of Reasons for Rejection and English language translation issued in corresponding Japanese Patent Application No. 2015-517565, dated Mar. 28, 2017, 6 pages. |
Onders R.,, “A Diaphragm Pacing as a Short-Term Assist to Positive Pressure Mechanical Ventilation in Critical Care Patients,” Chest, Oct. 24, 2007, vol. 132(4), pp. 5715-5728. |
Onders R.,, “Diaphragm Pacing for Acute Respiratory Failure,” Difficult Decisions in Thoracic Surgery, Chapter 37, Springer-Verlag, 2011, M.K. Ferguson (ed.), pp. 329-335. |
Onders R, et al., “Diaphragm Pacing with Natural Orifice Transluminal Endoscopic Surgery: Potential for Difficult-To-Wean Intensive Care Unit Patients,” Surgical Endoscopy, 2007, vol. 21, pp. 475-479. |
Pavlovic D., et al., “Diaphragm Pacing During Prolonged Mechanical Ventilation of the Lungs could Prevent from Respiratory Muscle Fatigue,” Medical Hypotheses, vol. 60 (3), 2003, pp. 398-403. |
Planas R.F., et al., “Diaphragmatic Pressures: Transvenous vs. Direct Phrenic Nerve Stimulation,” Journal of Applied Physiology, vol. 59(1), 1985, pp. 269-273. |
Romanovsky, A.A., et al., “The Vagus Nerve in the Thermoregulatory Response to Systemic Inflammation,” American Journal of Physiology, vol. 273 (1 Pt 2), 1997, pp. R407-R413. |
Salmela L., et al., “Verification of the Position of a Central Venous Catheter by Intra-Atrial ECG. When does this method fail?,” Acta Anasthesiol Scand, vol. 37 (1), 1993, pp. 26-28. |
Sandborn W.J., “Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis,” Annals of Internal Medicine, vol. 126 (5), Mar. 1, 1997, pp. 364-371. |
Sandoval R., “A Catch/Ike Property-Based Stimulation Protocol for Diaphragm Pacing”, Master of Science Coursework project, Simon Fraser University, Mar. 2013. |
Sarnoff, S.J. et al., “Electrophrenic Respiration,” Science, 1948, vol. 108, p. 482. |
Sato E., et al., “Acetylcholine Stimulates Alveolar Macrophages to Release Inflammatory Cell Chemotactic Activity,” American Journal of Physiology, vol. 274 (Lung Cellular and Molecular Physiology 18), 1998, pp. L970-L979. |
Sato, K.Z., et al., “Diversity of mRNA Expression for Muscarinic Acetylcholine Receptor Subtypes and Neuronal Nicotinic Acetylcholine Receptor Subunits in Human Mononuclear Leukocytes and Leukemic Cell Lines,” Neuroscience Letters, vol. 266 (1), 1999, pp. 17-20. |
Schauerte P., et al., “Transvenous Parasympathetic Nerve Stimulation in the Inferior Vena Cava and Atrioventricular Conduction,” Journal of Cardiovascular Electrophysiology, vol. 11 (1), Jan. 2000, pp. 64-69. |
Schauerte P.N., et al., “Transvenous Parasympathetic Cardiac Nerve Stimulation: An Approach for Stable Sinus Rate Control,” Journal of Cardiovascular Electrophysiology, vol. 10 (11), Nov. 1999, pp. 1517-1524. |
Scheinman R.I., et al., “Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids,” Science, vol. 270, Oct. 13, 1995, pp. 283-286. |
Sher, M.E., et al., “The Influence of Cigarette Smoking on Cytokine Levels in Patients with Inflammatory Bowel Disease,” Inflammatory Bowel Diseases, vol. 5 (2), May 1999, pp. 73-78. |
Steinlein, O., “New Functions for Nicotinic Acetylcholine Receptors?,” Behavioural Brain Research, vol. 95, 1998, pp. 31-35. |
Sternberg E.M., (Series Editor) “Neural-Immune Interactions in Health and Disease,” The Journal of Clinical Investigation, vol. 100 (11), Dec. 1997, pp. 2641-2647. |
Sykes., A.P., et al., “An Investigation into the Effect and Mechanisms of Action of Nicotine in Inflammatory Bowel Disease,” Inflammation Research, vol. 49, 2000, pp. 311-319. |
Toyabe S., et al., “Identification of Nicotinic Acetylcholine Receptors on Lymphocytes in the Periphery as well as Thymus in Mice,” Immunology, vol. 92, 1997, pp. 201-205. |
Van Dijk A.P.M., et al., “Transdermal Nicotine Inhibits Interleukin 2 Synthesis by Mononuclear Cells Derived from Healthy Volunteers,” European Journal of Clinical Investigation, vol. 28, 1998, pp. 664-671. |
Wanner, A. et al., “Trasvenous Phrenic Nerve Stimulation in Anesthetized Dogs,” Journal of Applied Physiology, 1973, vol. 34 (4), pp. 489-494. |
Watkins L.R., et al., “Blockade of Interleukin-1 Induced Hyperthermia by Subdiaphragmatic Vagotomy: Evidence for Vagal Mediation of Immune-Brain Communication,” Neuroscience Letters, vol. 183, 1995, pp. 27-31. |
Watkins L.R., et al., “Implications of Immune-to-Brain Communication for Sickness and Pain,” PNAS (Proceedings of the National Academy of Sciences of the USA), vol. 96 (14), Jul. 6, 1999, pp. 7710-7713. |
Whaley K., et al., “C2 Synthesis by Human Monocytes is Modulated by a Nicotinic Cholinergic Receptor,” Nature, vol. 293, Oct. 15, 1981, pp. 580-582 (and reference page). |
Escher, Doris J.W. et al., “Clinical Control of Respiration by Transvenous Phrenic Pacing,” American Society for Artificial Internal Organs: Apr. 1968—vol. 14—Issue 1—pp. 192-197. |
Ishii, K. et al., “Effects of Bilateral Transvenous Diaphragm Pacing on Hemodynamic Function in Patients after Cardiac Operations,” J. Thorac. Cardiovasc. Surg., 1990. |
Number | Date | Country | |
---|---|---|---|
20190030333 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
61662578 | Jun 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14410022 | US | |
Child | 16114064 | US |